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Abstract
Targeted inhibition of PI3K, mTOR, and IGF1R for the treatment of
undifferentiated pleomorphic sarcoma
Caitlin Denise May, BS
Supervisory Professor: Keila E. Torres, MD, PhD
Undifferentiated pleomorphic sarcoma (UPS) is an aggressive mesenchymal malignancy
largely devoid of indicators for its originating tissue. Surgery remains the standard of care,
as radiation therapy and systemic chemotherapy have limited efficacy in UPS patients with
localized and metastatic disease, respectively. Therefore, it is imperative to identify and
evaluate novel therapeutic targets in UPS in order to provide more efficacious treatment
options

for

patients.

Previous

studies

have

revealed

that

members

of

the

phosphatidylinositol-3-kinase/mammalian target of rapamycin (PI3K/mTOR) signaling
pathway can be used to predict patient outcome in cohorts containing patients with various
subtypes of soft tissue sarcoma. Furthermore, we have previously shown that high levels of
phosphorylated AKT correlate to poorer disease-specific survival in UPS patients, indicating
that PI3K/mTOR activity may contribute to the aggressiveness of disease. In this
dissertation, we demonstrate that the PI3K/mTOR pathway is active in UPS patient-derived
tumor samples and cell strains/lines. Pharmacologic blockade of this pathway using
second-generation dual PI3K/mTOR small molecule inhibitors as single agents attenuates
UPS cell proliferation, migration, and invasion in vitro. In addition, daily or twice daily drug
administration reduces tumor volume and weight in a mouse model harboring a UPS tumor
implant. However, single agent therapy was insufficient to eliminate tumor growth, and
immunohistochemical analysis revealed that PI3K/mTOR inhibition activates insulin-like
vii

growth factor 1 receptor (IGF1R), potentially as a mechanism of adaptive resistance.
Combined inhibition of PI3K, mTOR, and IGF1R via small molecule inhibitors resulted in a
drastically reduced tumor volume in vivo, despite the lack of substantial antiproliferative
effects in vitro. Furthermore, the drug combination significantly decreased UPS cell
migration and invasion, due in part to the re-localization of the cyclin-dependent kinase
inhibitor p27KIP1 to the nucleus. Taken together, our data indicate that targeted inhibition of
key nodes in the PI3K/mTOR pathway in combination with IGF1R reduces UPS
tumorigenicity and should be further explored as a novel therapeutic avenue for UPS
patients.
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Chapter 1
Introduction

1.1 Soft tissue sarcoma
Soft tissue sarcoma (STS) accounts for approximately 1% of adult and 7-15% of
pediatric cancers, with more than 12,000 new diagnoses and 5,000 deaths related to
STS in the United States annually (1-3). The term STS does not refer to a single entity;
rather, it encompasses more than 80 histologically distinct subtypes of rare
mesenchymal malignancies, classified and named according to their putative or known
originating tissue (4, 5). As these tumors are putatively derived from connective tissues
or more primitive precursor cells, including fat, nerve, and muscle, STS can develop in
all regions of the body, most commonly in the extremities (5, 6). The standard of care is
surgical resection, as many STS patients have limited response to conventional
chemotherapies (4, 5). Currently, the five-year overall survival rate for all STS patients
with localized disease is approximately 82%; for patients with metastatic disease,
survival drops dramatically to 18% (7, 8).
STS can be further characterized into two categories based on genomic criteria (913). The first includes those associated with specific recurring genetic alterations and
relatively simple karyotypes. The second is comprised of complex and unbalanced
karyotypes and inherent high levels of genomic instability and include tumors that are
generally more pleomorphic. Undifferentiated pleomorphic sarcoma, previously termed
malignant fibrous histiocytoma, is one such karyotypically complex STS subtype (1315).
1

1.2 Undifferentiated pleomorphic sarcoma
Reclassification of malignant fibrous histiocytoma
Malignant fibrous histiocytomas (MFHs) were once the most commonly diagnosed
STS in adults, accounting for nearly 40% of cases in the 1970s-1990s (16). First
described in the early 1960s, this STS subtype was thought to be derived from
histiocytes (local tissue macrophages) which could assume fibroblastic characteristics
(17, 18). MFHs display a wide range of morphological patterns that include storiform
(cartwheel-like)-pleomorphic, myxoid, giant cell, and inflammatory growth patterns (19,
20). The inclusive nature caused concern in some pathologists that MFH was being
over-diagnosed (20-22). Moreover, it was proposed that the pleomorphic growth
pattern observed in MFH represented a specific morphology, rather than an STS
subtype (23, 24).
During the 1990s and early 2000s, the majority of MFH cases were reclassified as
specific STS subtypes or other non-mesenchymal neoplastic entities, such as
melanoma or poorly differentiated carcinoma, as a result of improved diagnostic
techniques (25-28). Furthermore, identification of cell type-specific markers detectable
by immunohistochemistry revealed that many MFH cases more closely resembled
stromal spindle cells such as fibroblasts or myofibroblasts, rather than histiocytes (29).
In 2002, the World Health Organization (WHO) designated the myxoid and angiomatoid
subtypes of MFH as distinct diagnostic entities; moreover, the remaining tumors
previously called MFHs were reclassified as undifferentiated pleomorphic sarcomas
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(UPSs) (22, 30). In 2013, the UPS concept was further refined to account for nonpleomorphic histologies (31).
Incidence and clinical features
UPS accounts for approximately 5-15% of STS cases and is the most commonly
diagnosed STS subtype in patients over 40 years of age, with a slight predominance
towards males (1.2 to 1) (4, 13, 21, 22). These tumors are generally higher grade,
deep-seated masses most often located in the lower extremity and, to a lesser extent,
the upper extremity and retroperitoneum (4, 5, 13, 30). UPSs are often asymptomatic,
with only extremely fast growing tumors tending to cause discomfort and approximately
5% of patients have evidence of metastatic disease at time of initial diagnosis (30).
Molecular characteristics
The key defining characteristic of UPS is the lack of a distinct discernible line of
differentiation able to be identified by electron microscopy, immunohistochemistry, or
other methodologies (32). Therefore, UPS is considered a diagnosis of exclusion,
reserved for any STS with a pleomorphic or spindle cell histology and an absence of
specific diagnostic markers that cannot be placed in another diagnostic category.
However, recent reports have suggested that UPS may arise from mesenchymal stem
cells (MSCs) which are malignantly transformed through the inactivation of the Wnt
pathway and/or the activation of known oncogenes (33-36). The broader application of
these findings to the broad class of UPS is not known.
In contrast to STS subtypes characterized by chromosomal translocations or gene
amplifications or mutations, UPSs are karyotypically complex malignancies with nonrecurrent chromosomal gains and losses. Reports of specific recurring aberrations
3

unique to UPS are rare. However, several studies have reported similar chromosomal
rearrangements in UPS and leiomyosarcoma (LMS), a STS subtype showing smooth
muscle differentiation (37-39). Additionally, transcriptome analyses could not
distinguish UPS from other pleomorphic STS subtypes, further confounding differential
diagnoses (40-43).
Available treatment options
As with most STS, surgical resection is the standard-of-care for patients with
localized tumors (11, 44, 45). Chemotherapy and/or radiation therapy has been used in
conjunction with surgery for patients with large (>5 cm in diameter) and/or aggressive
disease. For patients with metastatic or unresectable disease, chemo- and/or
radiotherapy are the only available therapeutic options (45). However, like other
subtypes of STS, UPS is generally chemoresistant to most available systemic therapies
(46). In addition, clinical trials evaluating imatinib, sunitinib, or other targeted therapies
against receptor tyrosine kinases (RTKs) which have proved effective in other STS
subtypes have reported poor response rates in UPS patients (47-50).
Patient outcome
The local recurrence rate for patients with sporadic UPS is approximately 19-31%
(51-54). More than one-third of UPS patients will experience metastatic disease, most
often to the lung (80%), bone (8%), or liver (1%) (5, 51-54). The five-year survival rate
for patients with sporadic UPS is only 65-70% (51-54).
Radiation-associated UPS
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Neoadjuvant or adjuvant radiation therapy is often a part of a multidisciplinary
treatment regimen for cancer patients. A rare consequence of radiation therapy is the
development of a second malignancy. STS is one of the most common types of postradiation tumors, with an incidence rate from 0.03% - 0.80% (5, 55). In order for a
tumor to be classified as a radiation-associated STS (RA-STS), it must develop in an
area of the body which was exposed to radiation, such as a treatment modality for an
unrelated disease. The median latency between initial radiation exposure and STS
development has been reported to be approximately 8-10 years, although the
mandatory latency period for diagnosis has not yet been explicitly defined (56-58).
Approximately 25-36% of RA-STS are classified as radiation-associated UPS (RAUPS), which in turn account for 3% of all UPS cases (30, 31, 58, 59). Patients with RAUPS generally have a poorer prognosis than those with sporadic UPS, with a 5-year
disease-specific survival rate of 36-52% and a recurrence rate of 55% (56-58, 60).
1.3 The PI3K/mTOR signaling cascade
The phosphatidylinositol-3-kinase/mammalian target of rapamycin (PI3K/mTOR)
signaling axis is summarized in Figure 1. Briefly, PI3K is composed of two subunits: the
p110α catalytic subunit and the p85 regulatory subunit. Activation of PI3K can be
initiated when a ligand binds to a RTK, resulting in phosphorylation of tyrosine residues
located on the intracellular portion of the RTK (61, 62). These phosphotyrosines recruit
PI3K to the cell membrane by providing docking sites for the p85 subunit of PI3K,
causing a conformational change in the p85 subunit which allows for p110α catalytic
activity

(63,

64).

Activated

PI3K

phosphatidylinositol-3,4,5-triphosphate

then

generates

(PIP3)

phosphatidylinositol-4,5-bisphosphate (PIP2)
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the

through

second

messenger

phosphorylation

of

(65). PIP3 is able to recruit the

serine/threonine

kinase

AKT

(also

called

protein

kinase

B;

PKB)

and

3-

phosphoinositide-dependent kinase 1 (PDK1) to the plasma membrane by providing
docking sites for the proteins’ pleckstrin homology domains. PDK1 phosphorylates AKT
at T308 in the activation loop; an additional phosphorylation on S473 by the
mammalian target of rapamycin complex 2 (mTORC2) is essential for the full activation
of the protein (65, 66). Activated AKT promotes cellular processes like proliferation,
survival, and motility through the phosphorylation of downstream effector molecules
(67-69).
The serine/threonine kinase mTOR is a member of the PI3K-related kinase family
due to the strong homology between their catalytic domains (70). mTOR is essential for
the integration of extracellular and intracellular stimuli to coordinate the activation of
metabolic processes which support cell growth, proliferation, and survival; furthermore,
there is evidence that mTOR can regulate cell motility (70-72). Mammalian target of
rapamycin complex 1 (mTORC1) and mTORC2 are two large multiprotein complexes
which contain mTOR and are linked to PI3K signaling, but vary in both protein
composition and function (73-75). In addition, mTORC1 is sensitive to the macrolide
rapamycin, while mTORC2 is not directly inhibited by the compound; however,
sustained rapamycin treatment can block mTORC2 function (75-77).
The regulation and function of mTORC1 has been extensively characterized.
mTORC1 can be activated in response to several stimuli, including nutrient levels, cell
energy status, and growth factors (70). Stimulation of upstream RTKs by growth factors
results in PI3K activity and AKT phosphorylation. AKT indirectly activates mTORC1
through the inhibitory phosphorylation of tuberous sclerosis 2 (TSC2) (78-80). The
TSC1/2 heterodimer acts as a GTPase activating protein (GAP) and promotes the
6

GDP-bound (inactive) state of RAS homologue enriched in brain (RHEB), a small G
protein essential for mTORC1 activation (81, 82). Inhibition of the TSC1/2 complex
allows GTP-bound (active) RHEB to bind and activate mTORC1 (83).
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Figure 1.

The

PTEN–

PI3K–

AKT–

mTOR

pathway.

Phosphatase and tensin homologue (PTEN) opposes phosphoinositide 3-kinase
3
(PI3K)
function, leading to inactivation of AKT and mammalian target of rapamycin (mTOR) signalling.
Following PTEN loss, phosphatidylinositol
phosphatidylinositol-3,4,5-trisphosphate
trisphosphate (PtdIns(3,4,5)P3) accumulation
recruits the pleckstrin homology (PH) domain
domain-containing
containing proteins AKT and 3-phosphoinositide3
dependent kinase 1 (PDK1). Once positioned at the membrane, AKT is activated by PDK1PDK1
mediated phosphorylation at Thr308 and phosphorylation at Ser473 b
by
y mTOR complex 2
(mTORC2; composed of mTOR, DEP domain
domain-containing mTOR-interacting
interacting protein (DEPTOR),
mammalian lethal with SEC13 protein 8 (mLST8), stress
stress-activated
activated MAP kinase-interacting
kinase
protein 1 (mSIN1), Pro-rich
rich protein 5 (PRR5; also known as PROTOR) and
a
rapamycin
insensitive companion of mTOR (RICTOR)) (a). Active AKT drives cell survival, proliferation
and cellular metabolism through inhibitory phosphorylation of downstream proteins, including
glycogen synthase kinase 3 (GSK3), forkhead box O (FOXO), peroxisome proliferator-activated
proliferator
8

receptor-γ (PPARγ) co-activator 1α (PGC1) and p27, and through activatory phosphorylation of
ectonucleoside triphosphate diphosphohydrolase 5 (ENTPD5), sterol-responsive elementbinding protein 1C (SREBP1C), AS160 and S phase kinase-associated protein 2 (SKP2) (b).
AKT can also activate mTORC1 (composed of mTOR, DEPTOR, mLST8, 40 kDa Pro-rich
AKT1 substrate 1 (PRAS40) and regulatory associated protein of mTOR (RAPTOR)) by
mediating the inhibitory phosphorylation of its negative regulators tuberous sclerosis protein 2
(TSC2) and PRAS40 (c). TSC2 is also phosphorylated by extracellular signal-regulated kinase
(ERK), which inhibits the ability of TSC2 to function as a GTPase-activating protein (GAP)
towards RAS homologue enriched in brain (RHEB), whereas AMP-activated protein kinase
(AMPK)-mediated phosphorylation positively regulates the GAP activity of TSC2 (d). mTORC1
phosphorylates p70 ribosomal protein S6 kinase (S6K) and eukaryotic translation-initiation
factor 4E (eIF4E)-binding protein 1 (4EBP1) to activate protein translation and cell survival (e).
p90 ribosomal protein S6K (RSK)-mediated phosphorylation of RAPTOR contributes the
activation of mTORC1 signalling, whereas AMPK-mediated phosphorylation of RAPTOR
results in the inhibition of mTORC1 signalling (f). Genetic inactivation or pharmacological
inhibition of mTORC1 can activate AKT by preventing a negative feedback loop mediated by
the mTORC1–S6K-induced phosphorylation of insulin receptor substrate 1 (IRS1) and growth
factor receptor-bound protein 10 (GRB10) (g). Blue- and red-coloured molecules represent
activators and repressors of the signalling pathway, respectively. GF, growth factor; HIF1,
hypoxia-inducible factor 1; LKB1, liver kinase B1; MEK, mitogen-activated protein kinase
kinase; RTK, receptor Tyr kinase.
Reprinted by permission from Macmillan Publishers Ltd: [Nature Review Molecular Cell
Biology] (84), copyright 2012.

9

Once activated, mTORC1 is able to positively regulate cell metabolism and
biosynthesis through the promotion of anabolic processes, which it achieves by
phosphorylating several downstream proteins. In particular, activated mTORC1
increases protein synthesis by phosphorylating the eukaryotic initiation factor 4E
(eIF4E)-binding protein 1 (4EBP1) and the p70 ribosomal S6 kinase (S6K) (73, 74, 85,
86). Phosphorylation of the translational repressor 4EBP1 blocks its binding to eIF4E
and thus facilitates the initiation of cap-dependent translation (87, 88). Similarly, S6K
activation also promotes cap-dependent translation and elongation; furthermore, S6K
promotes ribosome biogenesis via phosphorylation of S6 ribosomal protein (S6RP) (89,
90).
Compared to mTORC1, not much is currently known about mTORC2 regulation and
function. Like mTORC1, mTORC2 is a regulator of cell metabolism, despite not
showing any sensitivity towards cellular nutrient levels. Rather, activation of mTORC2
is dependent on growth factor-mediated PI3K activation and the subsequent generation
of PIP3, although the details of mTORC2 activation are poorly understood (91). In
addition, mTORC2-mediated phosphorylation of AKT results in maximal activation of
the kinase and regulates cancer cell migration and invasion, further linking mTORC2 to
PI3K signaling (66, 92).
Implication of the PI3K/mTOR signaling pathway in tumorigenesis
The PI3K/mTOR pathway is one of the most commonly activated pathways in
cancer (61, 93-95). The tumorigenic potential of the PI3K/mTOR pathway lies within its
regulation of cellular processes such as cell growth, proliferation, migration, and
angiogenesis; furthermore, constitutive activation of this pathway has been linked to
10

resistance to systemic chemotherapies and inhibition of specific molecule targets (62,
69, 95-97). Aberrant or constitutive activation can be achieved in cancer cells through
upregulation of receptor tyrosine kinase signaling, activating mutations in molecular
pathway components (such as PIK3CA), and/or loss of tumor suppressors like the
phosphatase and tensin homologue (PTEN) (61, 94, 95).
Oncogenic PI3K/mTOR signaling contributes to cancer cell proliferation,
migration, and invasion in part through its regulation of the cyclin-dependent kinase
inhibitor (CDKi) p27Kip1 (hereafter called p27) (72, 98-100) (Figure 1, 2). In normal cells,
p27 functions as a master regulator of cell proliferation through its direct interactions
with cyclin-CDK complexes. In G0 and early G1, nuclear p27 blocks the G1-S transition
by binding to and inhibiting cyclin E-CDK2; in late G1, cytoplasmic p27 promotes G1
progression by facilitating the assembly and import of cyclin D-CDK4/6 complexes
(100-102). Furthermore, the contribution of p27 activity in cell motility has been
observed independently of its CDK-regulatory functions (98, 99, 103).
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Figure 2. p27 plays multifaceted roles in the regulation of cell proliferation and cell
migration. This schematic depicts p27 regulation and function as it relates to the protein's
subcellular localization. While in the nucleus, p27 binds to and inhibits cyclin E-CDK2,
E
preventing G1-S
S transit. Following SRC/ABL
SRC/ABL-mediated
mediated tyrosine phosphorylation and cyclin EE
CDK2–mediated
mediated T187 pho
phosphorylation,
sphorylation, nuclear p27 is targeted for SCFSKP2-dependent
degradation, allowing cell cycle progression. S10 phosphorylation promotes nuclear export;
whereas in the cytoplasm, p27 may play several roles. Oncogenic signal transduction via
PI3K/PDK1 or Ras/MAPK
MAPK results in the hyperactivation of several AGC family kinases
(including AKT, SGK, and RSK), which all mediate C
C-terminal
terminal phosphorylation of p27 at T157
and T198. These phosphorylation events cooperate to sequester and stabilize p27 within the
12

cytoplasm, where it promotes cell proliferation (via cyclin D-CDK4 assembly) and cell motility
(via inhibition of RhoA/ROCK signaling). Potential sites of targeted therapeutic intervention are
highlighted in the figure.
Reprinted from Clinical Cancer Research, 2011, 17 (1), 12-18, SA Wander, D Zhao and JM
Slingerland, p27: A Barometer of Signaling Deregulation and Potential Predictor of Response
to Targeted Therapies, with permission from AACR (102).
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Changes in p27 levels during the cell cycle are generally post-translationally
regulated. p27 translation and stability are maximal during G0 and early G1, where it
binds cyclin E-CDK2 and inhibits the G1-S transition (104-107). These levels begin to
fall during G1 progression due to a series of phosphorylation events which target p27
for nuclear export and/or proteolysis. In early G1, members of the ABL and SRC kinase
family phosphorylate p27 on several tyrosine residues (Y74, Y88, and Y89) on the
CDK-inhibitory domain (108, 109). This allows p27-bound cyclin E-CDK2 to further
phosphorylate p27 on T187, which targets p27 for proteolysis by SCFSKP2 (S-phase
kinase associated protein 1 [SKP1]/Cullin/F-box protein: SKP2 complex, E3 ubiquitin
ligase) (99, 108, 109). Interestingly, a recent study reported that mTORC2 reduced
nuclear p27 levels through the upregulation of the SKP2 ubiquitin ligase complex
independently of phosphorylation of T187, demonstrating that PI3K/mTOR signaling
can directly regulate nuclear p27 protein levels (110).
Subcellular localization can also regulate p27 function (Figure 2). Phosphorylation
of p27 on S10 by kinase-interacting stathmin (KIS) or minibrain-related kinase (MIRK)
during early G1 promotes nuclear export of p27 by exportin 1, preventing p27-mediated
cyclin E-CDK2 inhibition and targeting p27 for proteolysis by a SCF-independent
mechanism (111-115). Cytoplasmic p27 is further phosphorylated by AKT at T157 and
T198, effectively blocking its nuclear import while increasing its cytoplasmic stability;
furthermore, these modifications promote the assembly of cyclin D-CDK4/6-p27
complexes (116-120). Further phosphorylation of these complexes enables their
nuclear import and promotes subsequent cell cycle progression (99).
Cytoplasmic sequestration of p27 as a result of constitutive PI3K/mTOR signaling
can facilitate increased cancer cell migration and invasion through the inhibition of the
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RhoA/ROCK pathway (98, 100, 121). This pathway mediates the reorganization of the
actin cytoskeleton and therefore regulates cell morphology, adhesion, and migration.
The small GTPase RhoA activates Rho-associated kinase (ROCK), which in turn
activates LIM kinase (LIMK) (103, 122, 123). LIMK negatively regulates cofilin, a
member of the actin-depolymerizing protein (ADP) family which dissembles actin
filaments. As a result, there is an increase in the formation and stability of actin stress
fibers and focal adhesions, which promotes cell adhesion. Cytoplasmic p27 directly
binds and inhibits RhoA by preventing RhoA from binding its upstream activators, Rhoguanine exchange factors (Rho-GEFs) (124). The resulting actin cytoskeleton instability
and loss of stress fibers and focal adhesions following RhoA pathway inhibition
facilitates cell migration.
Prognostic potential of PI3K/mTOR pathway members
The PI3K/mTOR pathway has been reported as a driver of tumorigenesis in
numerous STS subtypes (125-129). In addition, markers of pathway activation have
been investigated as molecular prognosticators for disease progression and outcome
for STS patients. Constitutive activation of the pathway, as measured by the expression
of activated (phosphorylated) pathway components AKT, mTOR, S6K, and 4EBP1,
correlated with poor prognosis for STS patients (130-133). Furthermore, two studies
identified phosphorylated AKT as an independent negative prognosticator for overall
survival (OS) and disease-specific survival (DSS), while a third found that high levels of
activated AKT correlated to a higher probability of metastatic disease (130, 132, 134).
Similarly, previous work from our lab focusing on UPS patients determined that the high
level of phosphorylated AKT expressed by a subset of tumors (approximately 20% of
the cohort) significantly correlated to shorter DSS (135).
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Targeted therapy against PI3K/mTOR signaling and the potential for resistance
As constitutive PI3K/mTOR signaling is frequently observed in cancer and
contributes to tumorigenesis, disease progression, and resistance to systemic and
targeted therapies, recent drug development efforts have focused on specific small
molecule inhibitors against the PI3K/mTOR pathway (62, 85, 93, 136-139). However,
many studies have reported limited efficacy and/or resistance to these targeted agents,
often resulting in activation of compensatory signaling pathways, suggesting that
combination therapy involving PI3K/mTOR pathway inhibition may have superior antitumor results (61, 95, 140-145).
The PI3K/mTOR pathway is regulated by several negative feedback loops which
are disrupted upon targeted inhibition of the pathway members (70, 95). Both mTORC1
and its downstream kinase S6K negatively regulate growth factor signaling by
phosphorylating the adaptor protein insulin receptor substrate 1 (IRS1) and reducing its
stability (74, 146, 147). Inhibition of aberrant mTORC1 activity by treatment with
rapamycin or its derivatives (called rapalogues) relieves the negative regulation of IRS1
by S6K and mTORC1 and activates the PI3K-AKT axis via RTK signaling, resulting in
increased levels of phosphorylated AKT (140, 148, 149). In order to overcome the
compensatory increase in PI3K signaling, treatment strategies expanded to include
targeted therapy of both mTORC1 and mTORC2 (95). In addition, some second
generation mTOR inhibitors also block PI3K catalytic activity as a result of the high
structural homology and sequence identity in their ATP binding domains (93, 150).
Dual PI3K/mTOR inhibitors efficiently blocked AKT activation and reduced cancer
cell proliferation, generally through a G1 cell cycle arrest, although an increase in
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apoptosis has been reported; in addition, treatment with dual inhibitors attenuated
xenograft growth in vivo (151-160). Blockade of the PI3K/mTOR pathway via the use of
dual inhibitors enhanced or restored sensitivity to chemotherapy, radiation therapy, or
other targeted therapies (161-173). These preclinical data and safety profiles have
promoted the evaluation of several dual PI3K/mTOR inhibitors in early stage clinical
trials both alone and in combination with chemotherapy or other targeted agents (174180).
Although dual PI3K/mTOR inhibitors display strong anti-cancer effects in preclinical
and clinical settings, adaptive resistance through alternative pathway activation and
upregulation of RTK activity has been reported following treatment (61, 71, 144, 148,
181, 182). One potential resistance mechanism involves insulin-like growth factor 1
receptor (IGF1R). Increased expression and activation of IGF1R was noted in matrixattached ovarian cancer cells treated with the dual PI3K/mTOR inhibitor BEZ235;
shRNA-mediated knockdown of IGF1R restored sensitivity to PI3K/mTOR inhibition
(145). In addition, targeted AKT inhibition induced IGF1R expression and activation
through the activation of the FOXO transcription factor family and the suppression of
S6K activity (142). Furthermore, synergistic proapoptotic and anti-tumorigenic effects
were observed in models of hepatocellular carcinoma treated with the combination of
PI3K/mTOR pathway inhibitors RAD001 (against mTOR), MK2206 (against AKT), and
BEZ235 (against PI3K and mTOR) with the IGF1R-targeting agent AEW541 (167).
Taken together, these data indicate that a vertical blockade combining pharmacologic
blockade of PI3K/mTOR pathway with targeted IGF1R inhibition would prevent
resistance to single agent therapy and yield a superior therapeutic benefit.

17

1.4 Insulin-like growth factor 1 receptor (IGF1R) signaling
IGF1R is a tetrameric receptor tyrosine kinase composed of two half-receptors, each
containing an extracellular ligand-binding α-subunit and an intracellular β-subunit,
which is further divided into the transmembrane and catalytic domains (Figure 3). The
insulin receptor (IR) is similarly composed and highly homologous to IGF1R, with 84%
sequence identity in the kinase domain and 95% sequence identity in the ATP-binding
domain (183, 184). Furthermore, hybrid receptors consisting of one IGF1R halfreceptor and one IR half-receptor have been reported in cells that express both
receptors (185, 186). The extracellular domains of IGF1R can bind one of three
ligands: insulin-like growth factor 1 (IGF1), IGF2, or insulin. The sequence homology
between IGF1 and IGF2 is 62%, while the homology between the IGFs and insulin in
42% (187).
IGF1R preferentially binds IGF1 and binds IGF2 and insulin with a 5-10 and 100 fold
lower affinities, respectively (188). Ligand binding to the extracellular domains of IGF1R
results in a conformational change and subsequent autophosphorylation of tyrosine
residues 1131, 1135, and 1136 in the intracellular catalytic domain. These events
promote the phosphorylation of juxtamembrane tyrosines and C-terminus serines,
resulting in docking sites which recruit adaptor proteins to the receptor (189-191).
These proteins, such as IRS1-4 (IR substrate 1-4) or SHC (Src homology/collagen
domain protein), activate signaling through the PI3K/mTOR or mitogen-activated
protein kinase (MAPK) pathways. Signaling transduction through IGF1R and its
downstream pathways results in cell growth, proliferation, metabolism, and survival;
furthermore, IGF1R regulates migration, invasion, adhesion, and angiogenesis (191,
192).
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Figure 3. The components of the IGF system. IGF-I, IGF-II
II and insulin interact with their
cognate receptors as indicated. IGF
IGF-II
II has a high affinity for the insulin receptor isoform A (IR(IR
A) but not for IR-B. IGF-1R
1R and insulin receptor isoforms can form heterodimers, called hybrid
receptors. The function
unction of IGF
IGF-I and IGF-II
II is modulated by IGF binding proteins (IGFBP-1–6),
(IGFBP
which in their turn are subjected to cleavage by proteases.
Reprinted with permission from [The insulin
insulin-like
like growth factor system and sarcomas/ B Rikhof,
S de Jong, AJH Suurmeije
Suurmeijer,
r, C Meijer and WTA van der Graaf/The Journal of Pathology,
Volume 217, Issue 4. Copyright (c) [2008] [Pathological Society of Great Britain and Ireland]
(190).

19

Tumorigenic role of IGF1R
IGF1R is critical for malignant transformation by several oncogenes; furthermore,
IGF1R signaling facilitates cancer cell proliferation and survival, angiogenesis, and
metastasis through the activation of PI3K/mTOR and other downstream pathways (188,
191, 193-196). Cancer-specific amplifications of or mutations in IGF1R are rare; rather,
the main route of IGF1R dysregulation in tumorigenesis is aberrant activation due to
increased expression and/or the development of autocrine or paracrine signaling loops
(191, 196). Moreover, overexpression and/or activation of IGF1R have been reported in
cancer cells previously treated with inhibitors of the PI3K/mTOR pathway, indicating
that receptor activity can also circumvent targeted therapy (142, 145, 197).
In addition, IGF1R has been identified as a molecular prognosticator in numerous
cancers, including STS. High IGF1R expression is linked to tumor aggressiveness and
poor metastasis-free survival in myxoid liposarcoma and synovial sarcoma (198, 199).
Similarly, IGF1R expression inversely correlated with overall survival in MPNST and
rhabdomyosarcoma (133, 200, 201). In addition, IGF1R expression could distinguish
between low, intermediate, and high grade disease in multiple STS subtypes, including
UPS, with increasing levels of IGF1R corresponding to higher grade lesions (202).
Targeted therapy against IGF1R
In addition to identifying IGF1R as an important regulator of several tumorigenic
processes, preclinical studies also linked IGF1R activity with resistance to therapy
20

(189, 196, 203-207). Therefore several anti-IGF1R monoclonal antibodies (mAbs) and
small molecule inhibitors were developed (192, 208). mAbs against IGF1R or its
ligands function to prevent growth factor binding and subsequent signal transmission to
downstream pathways (mainly PI3K/mTOR) as well as to increase the rate of receptor
internalization, reducing the number of receptors on the cell surface, while small
molecule inhibitors block the ATP binding site of the receptor’s tyrosine kinase domain
(209). Small molecule inhibitors are generally less specific than mAbs, due to the high
homology between IGF1R and IR; however, some small molecule inhibitors show
selectivity towards IGF1R (209-212).
Several clinical trials evaluating IGF1R mAbs as single agent or in combination with
cisplatin or targeted chemotherapies were discontinued due to lack of efficacy, with one
Phase II trial reporting poorer overall patient survival in the treatment arm (213-215).
The failure of these trials to result in any anti-tumor effects could be attributed to
increased IR signaling. While targeting of IGF1R reduces the number of IGF1R
homodimers and hybrid IGF1R:IR heterodimers through receptor internalization, IR
homodimers are unaffected and expression has been reported to increase in response
to therapy, which would attenuate the response to mAb-mediated IGF1R inhibition
(213). In addition, the use of IGF1R mAbs has been linked to dysregulated endocrine
signaling through increased growth hormone levels which promotes IR activation
through increased IGF1 and insulin production (191, 208).
The disappointing results of initial clinical trials have highlighted the need to identify
predictive biomarkers to discern patient populations that could benefit from this type of
therapy (208, 214, 216). Furthermore, IGF1R-targeted therapy development has begun
to exploit the role of IGF1R as a mediator of chemoresistance. Several preclinical
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studies and clinical trials have evaluated combination therapy with an IGF1R inhibitor
and cytotoxic chemotherapy or other targeted agent (167, 217-222). Furthermore, the
identification of potential resistance mechanisms to IGF1R-targeted therapy is
prompting the evaluation of novel combinations for their anti-tumor efficacy. The
combination of anti-IGF1R mAbs with rapalogues has been investigated in Phase I
clinical trials in patients with advanced solid tumors, with some antitumor responses
reported (216, 223-225); however, additional clinical studies of the anticancer efficacy
of combined inhibition of IGF1R and other components of the PI3K/mTOR pathway
have yet to be conducted.
1.5 Hypothesis and specific aims
In summary, UPS is a karyotypically complex STS subtype with no discernible line
of differentiation, nor any specific recurring genetic aberrations (31). The absence of
consistent genomic abnormalities in UPS has hindered the identification and evaluation
of potential therapeutic targets. Furthermore, the moderate response of UPS patients to
available therapeutic options is reflected in the current five-year overall survival rate of
only 65-70%, highlighting the crucial need to identify and evaluate targeted therapies
for their efficacy (4, 5). Previous studies have revealed that active PI3K/mTOR
signaling denotes a worse prognosis for STS patients (131). Our lab has further shown
that 20% evaluated UPS patient samples expressed high levels of phosphorylated
AKT, which correlated to a poorer patient outcome (135). These findings indicate that
the PI3K/mTOR pathway may be a driver of UPS tumorigenesis and thus represents a
potential therapeutic target. However, IGF1R activation has been reported in response
to PI3K/mTOR inhibition, suggesting a potential mechanism of adaptive resistance
(142, 145).
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Therefore, I hypothesize that dysregulation of the PI3K/mTOR signaling axis
contributes to the aggressive nature of UPS and targeting specific components of this
pathway will have anti-tumorigenic effects; furthermore, combining targeted therapy
against PI3K/mTOR and IGF1R will yield a greater therapeutic benefit.
To pursue this hypothesis, I developed the following specific aims:
•

Specific Aim 1: Determine the activation status of the PI3K/mTOR signaling
cascade in UPS tumors and cell lines and investigate prognostic significance.

•

Specific Aim 2: Examine the consequences of therapeutic blockade of
PI3K/mTOR pathway components on the tumorigenic characteristics of UPS
cells.

•

Specific Aim 3: Evaluate the efficacy of PI3K/mTOR inhibition in combination
with targeted therapy against IGF1R to yield synergistic anti-tumorigenic effects.
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Chapter 2
Materials and Methods

Immunohistochemical and statistical analysis of UPS tissue microarrays (TMAs)
A previously constructed TMA comprised of sporadic-UPS tissue samples was
utilized for immunohistochemical analysis (n = 173); an additional TMA of RA-UPS
samples (n = 35) was developed as previously described and was included for analysis
(135). All samples evaluated were derived from primary tumors. Immunohistochemistry
for pAKT, AKT, pS6RP, S6RP, and p4EBP1 was performed by the histology core
facility at The Virginia Harris Cockrell Cancer Research Center at Science Park
histology core (Smithville, TX, USA). Immunohistochemistry for MET, cyclin D1,
pEGFR, IGF1R, c-KIT, PDGFRα, and PDGFRβ was performed by the MD Anderson
Cancer Center Clinical and Research Core facilities. Immunostaining for pIGF1R,
pMEK, MEK, pMET, and AXL was conducted in our laboratory as follows. Formalinfixed, paraffin-embedded tumor specimens were cut into 4µm sections, which were
deparaffinized in xylene and rehydrated using a graded ethanol series. Sections were
subjected to antigen retrieval at 100°C for 45 minutes in Tris-EDTA, pH 8 and
endogenous peroxidase blocking in 3% H2O2 in PBS for 12 minutes. Primary antibody
incubation took place at 4°C overnight using pIGF1R rabbit monoclonal antibody #3024
diluted 1:25, pMEK rabbit monoclonal antibody #2338 diluted 1:50, MEK rabbit
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polyclonal primary antibody #9122 diluted 1:50, pMET rabbit monoclonal antibody
#3077 diluted 1:100, or AXL rabbit monoclonal antibody #4566 diluted 1:100 (Cell
Signaling Technology). Primary antibody was visualized using the 4plus two-step HRP
detection

system

(Biocare

Medical)

and

diaminobenzidine.

Sections

were

counterstained with hematoxylin and mounted with Permount (Fisher).
The percentage of tumor cells expressing the marker was recorded. Cyclin D1
revealed a nuclear localization while pAKT, AKT, p4EBP1, and 4EBP1 showed both
cytoplasmic and nuclear staining. All other markers exhibited cytoplasmic localization.
For cyclin D1, AXL, c-KIT, pEGFR, IGF1R, PTEN, pS6RP, and p4EBP1, samples were
considered positive if ≥ 10% of cells were stained. For pMET, pIGF1R, pAKT, AKT, and
S6RP, samples were analyzed as 2 groups: negative/low (≤60% of cells positive for
stain) and high (>60% of cells positive). A regularly updated prospective database was
available for retrieval of clinicopathologic variables (age, sex, disease setting, and
tumor size [diameter in cm]) pertaining to UPS patient samples.
Mann-Whitney and Fisher’s exact tests were utilized to evaluate protein expression
differences between sporadic UPS and RA-UPS. Correlations between protein markers
were determined by Spearman’s rank correlation coefficient. Survival times were
estimated by Kaplan-Meier curves. Multivariate Cox regression models were
constructed to assess associations between protein expression and survival outcome
adjusting for clinical covariates. To construct the most parsimonious models, variables
in univariate analysis at p < 0. 10 were fitted in multivariate models. Overall survival
(OS) time was measured from date of diagnosis by pathological confirmation to date of
death of any cause or last day of follow-up and disease-specific survival (DSS) was
measured to date of sarcoma-related death or last day of follow-up. p values <0.05
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were considered statistically significant unless otherwise indicated. All analyses were
performed using SPSS version 21. Kaplan-Meier curves were constructed using
GraphPad Prism, version 6.05.
UPS cell isolation and tissue cultures
The isolation of UPS cells from patient tumor samples was conducted by our laboratory
with the approval of the Institutional Review Board at The University of Texas MD
Anderson Cancer Center (UTMDACC) and patients’ written informed consent. Surgical
specimens were obtained from 5 patients who presented at UTMDACC from July 2010
to November 2011. RIS-DL-620, UPS-186, and UPS-DL-511 were isolated as
previously described (226), while RIS-819.1 and UPS-DL-271.1 were isolated from
patient

surgical

specimens

serially

passaged

in

hairless

severe

combined

immunodeficient (SCID) mice. The clinical characteristics of these bioresources are
detailed in Table 1. In brief, fresh sterile samples from surgically resected tumors were
minced in 1x PBS and then digested via incubation with collagenase type I (3%),
DNase I (0.02%), and hyaluronidase (1.5 mg/ml) at 37 °C for 2–4 h. The sample
was strained through a wire mesh screen, and undigested tissue was discarded. After
centrifugation, washes, and resuspension in PBS, the sample was gently transferred to
Histopaque tubes containing 10 ml Histopaque (100%; Sigma) overlayed with 15 ml
of Histopaque (75%). The tubes were then centrifuged at 40 °C for 30 min at
1200 g. After centrifugation, tumor cells located in the top interface (over 75%
Histopaque) were collected and plated. Cells were cultured and passaged in DMEM
supplemented with 10% FBS and 1% penicillin/streptomycin. UPS-186 and RIS-819.1
were passaged more than 40 times and considered cell lines. UPS cell strains and cell
lines were validated by STR DNA fingerprinting using the Promega 16 High Sensitivity
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STR Kit (Catalog # DC2100). The STR profiles were compared to online search
databases (DSMZ/ATCC/JCRB/RIKEN) of 2455 known profiles; along with the MD
Anderson Characterized Cell Line Core (CCLC) database of 2556 know profiles. The
STR profiles of cell strains and cell lines matched originating tumor DNA fingerprints.
STR-confirmed cell strains and cell lines were deposited in an in-house cell bank and
were pulled every 9-12 months for experimental use to ensure low passage numbers
and no cross-contamination. The results of STR fingerprinting are presented in Table 2.
Bone-derived human mesenchymal stem cells were purchased from PromoCell (cat#
C-12974) and maintained in Mesenchymal Stem Cell Growth Medium (PromoCell, cat#
C-28010).
Drugs and vehicles
XL765 was provided by Sanofi-Aventis as part of a collaboration. BGT226 (NVPBGT226, cat# S2749) and AEW541 (NVP-AEW541, cat# S1034) were purchased from
Selleck Chemicals. All drugs were resuspended as stock concentrations in DMSO for in
vitro applications. For in vivo administration, XL765 was resuspended in water and 10
mM HCl. BGT226 was resuspended in N-Methyl-2-pyrrolidone (NMP) and this stock
solution was stable at 4°C for 1 week. Immediately prior to administration, the
NMP/BGT226 stock solution was diluted in PEG300 (10% NMP/BGT226 plus 90%
PEG300). AEW541 was solubilized in 25 mM L(+)-tartaric acid for use in mice.
Cell proliferation assay
Cell proliferation was evaluated using CellTiter 96 AQueous One Solution Cell
Proliferation

Assay

(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-

sulfophenyl)-2H-tetrazolium, inner salt; MTS) (Promega, cat# G3580) according to the
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manufacturer’s

instructions.

For

MTS

experiments

requiring

stimulation

with

recombinant IGF1 (R&D Systems, cat# 291-G1-200), cells were incubated with half the
total volume of DMEM-10% FBS with or without 2x concentrated dose(s) of drug(s) 24
hours after seeding. After 2 hours, the remaining media containing 40 ng/mL
recombinant IGF1 was added to the wells (final concentration: 20 ng/mL IGF1, 1x
concentrated drug).
Evaluation of drug synergism
The potential synergistic drug interactions between BGT226 and AEW541 were
analyzed by the Chou-Talalay method for drug combination (227). MTS assays were
used to quantify cell viability after 96 hours of treatment and cell proliferation relative to
the DMSO + recombinant IGF1 control was calculated. Drug concentrations along with
the corresponding drug effects (drug effect = 1 – relative cell proliferation) were entered
into the CompuSyn software (Version 1.0) and combination index (CI) values were
obtained. A CI value <1 indicates drug synergy; values near 1 designates additivity and
those >1 are indicative of antagonism. Heat maps displaying CI values and %drug
effects obtained from each combination were generated using Microsoft Excel
(Microsoft, Redmond, WA).
Preparation of whole cell lysates and immunoblotting
UPS cell lysates were made by scraping cells in whole cell lysis buffer (10% glycerol,
1% NP-40, 50 mM TrisCl, 150 nM NaCl, 50 mM NaF, 1mM EDTA, 2mM PMSF, 1 mM
Na3VO4, plus protease inhibitor [Roche cat# 11 697 498 001] and phosphastase
inhibitor cocktails #2 and #3 [Sigma cat# P5726 and P0044]). For assessment of drug
treatment on protein expression, cells were incubated with drug for the indicated time
28

point and immediately harvested. For AEW541 and combination treatments, cells were
incubated with or without drug for 2 hours, stimulated with 20 ng/mL recombinant IGF1
for 15 minutes, and harvested in whole cell lysis buffer.
Standard protocols for western blot analysis were followed. Commercially available
antibodies were used for detection of PI3K/mTOR and MAPK pathway components:
AKT (cat# 9272), pAKT S473 (#9271), S6K (#9202), pS6K T389 (#9206), 4EBP1
(#9452), p4EBP1 T37/46 (#2855), ERK (#9102), pERK T202/T204 (#9106), pMEK1/2
S221 (#2338), IGF1R (#3018), and pIGF1Rβ Y1135/1136/insulin receptor β
Y1150/1151 (#3024) (Cell Signaling Technology). Antibodies against p-p27 T157 (cat#
AF1555) and p-p27 T198 (cat# AF3994) were obtained from R&D Systems and antip27 (cat# sc-1641) and anti-β-actin-HRP (cat# sc-47778) were purchased from Santa
Cruz Biotechnology.
Reverse phase protein array (RPPA)
One sporadic UPS cell line and one RA-UPS cell line were exposed to 5 µM XL765 for
48 hours prior to harvest. RPPA protein expression profiles were generated by the
RPPA Core Facility at UTMDACC using standard procedures (228). Protein dilution
curves were fitted with the Supercurve fitting logistical model and RPPA data were
normalized to loading controls. Normalized data were transformed by log2 and used for
further analyses. Heat maps displaying the linear ratio of the protein expression of
XL765-treated cells by that of untreated control cells were created in Microsoft Excel.
Cell cycle and apoptosis assays
Cell cycle distribution was determined by propidium iodine-fluorescence associated
cell sorting (PI-FACS) analysis. Cells were treated with the indicated inhibitor for 48
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hours, then fixed in 70% ethanol. Fixed cells were resuspended in a PI staining solution
containing 75 µg/mL PI and 10 µg/mL RNase A. Apoptosis was measured in UPS cells
after 96 hours of treatment using the Apoptosis Detection Kit I (BD Biosciences cat#
556547) according to the manufacturer’s instructions. Cells in both early and late
stages of apoptosis were reported as total apoptosis. Cell cycle and apoptosis were
analyzed in a Gallios Flow Cytometer (Beckman Coulter) located in the Flow Cytometry
and Cellular Imaging Core at MDACC. Data from these experiments were analyzed
using the Multicycle Program in FCS Express (De Novo Software).
Assessment of in vitro migration and invasion
In vitro cell migration and invasion was assessed via modified Boyden chamber
assays. For migration analysis, 2.5 x 104 cells were resuspended in low-serum (1%
FBS) DMEM/F12 and seeded into the upper compartment of each BD BioCoat Control
Insert (cat# 354578). For invasion assays, cell number was increased to 5.0 x 104 and
cells were seeded in BD BioCoat Matrigel Invasion Chambers (cat# 354480).
DMEM/F12 supplemented with 5% FBS served as the chemoattractant in the lower
compartment. In assays interrogating the effects of PI3K/mTOR or IGF1R inhibition,
drug(s) were added to both the upper and lower compartment of the chamber at the
indicated concentrations. For experiments with AEW541 or combination treatment, the
lower

chamber

chemoattractant.

included

100

ng/mL

recombinant

IGF1

as

an

additional

After a 16 hour incubation at 37°C, cells were fixed with 10%

glutaraldehyde and stained with 0.2% crystal violet in 20% methanol. Chambers were
photographed at 20x magnification, with 5 images showing different fields of view taken
for each chamber. Migratory cells were quantified using ImageJ 1.47V software
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(http://rsbweb.nih.gov/ij/index.html) and invasive cells were counted manually (84, 229,
230).

In vivo tumor studies
All animal procedures were approved by the Institutional Animal Care and Usage
Committee (IACUC) at UTMDACC. Six-week old female hairless SCID mice (Charles
River Laboratory, Strain Code 488) were implanted in the flank with 2-3 mm pieces of
RIS-819.1 tumor. Therapeutic interventions began when tumors reached an average
volume of 100 mm3 in each group. BGT226 and AEW541 were administered daily (5
days/week unless otherwise indicated) via oral gavage. When tumors in the vehicle
arm reached a maximum volume of 1500 mm3, all animals were euthanized.
Immunohistochemical analysis of xenografts
Xenograft-derived specimens were analyzed for PI3K/mTOR signaling activity
through IHC for pAKT, pS6RP, and p4EBP1 by the histology core facility at the MD
Anderson Cancer Center at Science Park. These tissues were further interrogated by
immunostaining for Ki67 (cell proliferation marker) and cleaved caspase 3 (CC3;
apoptosis marker), which was performed by the MD Anderson Cancer Center Clinical
and Research Core facilities. IHC for pIGF1R was conducted in our laboratory as
described above.
Nuclear and cytoplasmic fractionation
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RIS-819.1 cells were treated with 1 µM AEW541, 25 nM BGT226, or a combination of
the two drugs in low serum (1% FBS) DMEM/F12 for 16 hours. Following treatment,
nuclear and cytoplasmic fractions were isolated using the NE-PER Cytoplasmic and
Nuclear Extraction Reagents (Pierce, cat#7833) per the manufacturer’s instructions.
Lamin A/C (Santa Cruz, cat# sc-6215) and α-tubulin (Santa Cruz, cat# sc-5286) were
used as nuclear and cytoplasmic purity controls, respectively. Densitometric
quantification of protein expression was performed with ImageJ 1.47V software
(http://rsbweb.nih.gov/ij/index.html).
Assessment of RhoA activity
UPS cells were grown to 70-80% confluency and serum starved (1% FBS in
DMEM/F12) for 16 hours. After stimulation with 5% FBS and 100 ng/mL IGF1 for 60
seconds, cells were immediately lysed. RhoA activity was detected using the G-LISA
RhoA Activation Assay (Cytoskeleton, Inc., cat# BK124) per the manufacturers’
instructions.
Statistical analysis of in vitro and in vivo experiments
Data are presented as the mean +/- the standard error of the mean (SEM). Each
experiment was repeated in triplicate unless otherwise indicated in the figure legend.
The Student’s t-test was used to evaluate statistically significant differences between
experiment groups. p values were considered statistically significant when p < 0.05.
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Chapter 3
PI3K/mTOR signaling is active in UPS patient samples.

A previous study by our research group revealed that 20% of sporadic UPS patient
samples examined harbored high levels of phosphorylated AKT (pAKT) and that
increased expression significantly correlated with disease-specific survival (DSS) in a
multivariate model. In our study, we utilized two UPS TMAs comprising 173 sporadic
and 35 RA-UPS samples to interrogate PI3K/mTOR pathway activity through the
expression of downstream effectors S6 ribosomal protein (S6RP; a surrogate for S6K
activity) and 4EBP1; a downstream transcriptional target, cyclin D1; and the tumor
suppressor PTEN, a negative regulator of PI3K activity. AKT expression was again
evaluated in these TMAs to maintain consistency with the inclusion of the newly
constructed TMA as well as to accommodate the longer follow-up period in the
previously utilized microarray. We also determined the expression level of AXL and cKIT as well as the levels of total and phosphorylated EGFR (epidermal growth factor
receptor), IGF1R, MET, and platelet-derived growth factor receptors A and B
(PDGFRA/B), as these upstream RTKs can stimulate PI3K/mTOR signaling. Finally, we
determined total and active MEK (mitogen-activated protein kinase kinase) expression
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to indicate activation of the MAPK (mitogen-activated protein kinase) pathway, which is
dysregulated in numerous cancer types and also can be activated in response to
PI3K/mTOR inhibition (231).
Tumor and patient characteristics are summarized in Table 3. The total cohort
consisted of 208 patients with a median age of 64 years old. All 208 samples were
obtained from primary/index tumors. The majority of tumors were high grade (76%),
located in the extremity (73%), and superficial (87%). Nearly one-third (31%) of patients
received chemotherapy, while 57% of patients were treated with radiation. The majority
of resection margins (70%) were negative.
Protein marker expression can vary based on disease setting
The majority of the biomarkers of interest (16/21, 76%) were able to be evaluated in
survival analysis. Homogenous expression of MET, PDGFRA, PDGFRB, and total and
phosphorylated MEK, was detected at high levels (>80% of cells strongly positive) in all
samples; therefore, these stains could not be stratified in univariate or multivariate
analysis (data not shown). The expression of evaluable protein markers for the entire
cohort, both combined and divided into disease settings (sporadic UPS and RA-UPS),
is summarized in Table 4. Positive expression (≥10% of cells positive for marker
presence) of AXL, pEGFR, and nuclear p4EBP1 was detected in the majority of
samples (52%, 74%, and 80% of samples, respectively). In addition, high expression
(>60% of cells positive) of nuclear pAKT and total S6RP was noted in 53% and 76% of
tumors, respectively. PTEN was expressed in most samples (96.0%), with only 10
samples exhibiting a loss. Interestingly, we noted that the expression of some markers
varied significantly depending on disease setting (sporadic versus radiation-associated
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UPS).. A higher percentage of sporadic UPS samples were posi
positive
tive for pEGFR than
RA-UPS
UPS (81% versus 45
45%, p < 0.001). Excitingly, more RA-UPS
UPS samples
sampl
were
positive for IGF1R (53%
% versus 25% of sporadic samples, p = 0.003); furthermore,
80% of RA-UPS
UPS samples exhibit high pIGF1R staining compared with only 29%
29 of

sporadic UPS samples (p < 0.001).
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The PI3K/mTOR pathway is active in a subset of UPS patient samples
In order to determine whether the PI3K/mTOR signaling cascade is activated, we
correlated the expression of active pathway components using a Spearman’s
correlation. Positive correlation coefficients obtained when pAKT, pS6RP, and p4EBP1
staining patterns (both cytoplasmic and nuclear) were examined indicated that the
PI3K/mTOR signaling cascade is active in UPS samples regardless of disease setting;
in addition, these correlations were strongly significant (Figure 4). As expected, PTEN
expression negatively correlated with all downstream effectors examined. Expression
of pIGF1R and pMET positively correlated with one another, while both negatively
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correlated with pEGFR. Active IGF1R expression weakly correlated with cytoplasmic
pAKT and pS6RP, while pEGFR significantly correlated with pS6RP and cytoplasmic
p4EBP1.
Several protein markers can predict OS and DSS for UPS patients
The follow-up period for patients ranged from 0.8 to 20.75 years. The median
overall survival (OS) was 8.5 years, with a 5-year survival estimate of 55% (Figure 5A).
The 5-year DSS was 63% (Figure 5B). A univariate Cox proportional hazard ratio
model determined that age (<61 years old), disease setting (sporadic), tumor size (<10
cm in diameter), and margins (negative) were significant prognosticators of both OS
and DSS (OS: hazard ratio [HR] 0.36, 0.44, 0.51, and 0.61, p < 0.001, <0.001, 0.001,
and 0.016; DSS: HR 0.41, 0.37, 0.48, and 0.62, p = 0.001, <0.001, 0.002, and 0.051,
respectively) (Table 5).
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Figure 4. Correlation of the expression of PI3K/mTOR pathway components and
upstream RTKs from TMA samples.

A heat map was generated using Spearman’s

correlation coefficients obtained from the correlation between the expression of PI3K/mTOR
signaling components and/or upstream RTKs. C = cytoplasmic stain, N = nuclear stain. Gold
indicates a positive correlation
correlation,, while blue indicates a negative correlation. Bold values = p <
0.05; bold and italicized values = p < 0.01; bold and italicized values surrounded by a bold box

= p < 0.001.
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Figure 5. Overall and
diseasespecific survival of UPS patients.

Kaplan-

Meier

curves depicting (A) OS and (B) DSS of the UPS patient cohort included in TMA analysis.
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Furthermore, univariate analysis revealed that better OS and DSS was predicted by
negative-low expression of pIGF1R (OS: HR 0.58, p = 0.036; DSS: HR 0.49, p = 0.022
DSS) and the presence of PTEN (OS: HR 7.70; DSS: HR 10.3, both: p < 0.001), while
worse survival outcomes were associated with negative pEGFR expression (OS: HR
1.81, p = 0.015, DSS: HR 1.94, p = 0.023; Figures 6 and 7). Negative-low staining for
nuclear AKT was significantly associated with improved OS (HR 0.61, p = 0.034).
Although not reaching statistical significance at p < 0.05, a strong trend revealed that
negative-low AXL and IGF1R expression was indicative of better OS (HR 0.66 and
0.67, p = 0.085 and 0.091, respectively) and negative expression of cyclin D1, a
downstream transcriptional target of the PI3K/mTOR pathway and a key regulator of
cell cycle progression through the G1/S checkpoint, correlated with a less favorable
DSS (HR 0.46, p = 0.060; Figure 8).
Clinical factors and PTEN loss retain prognostic value in multivariate analysis
Only those markers or clinicopathologic features that were found significant at p <
0.10 in univariate analysis were included in multivariate analysis. Age (<61 years old),
disease setting (sporadic), tumor size (<10 cm in diameter), margins (negative) and
PTEN expression maintained their prognostic value in the multivariate model for both
OS and DSS (Table 5). The prognostic value of AXL, cyclin D1, pEGFR, pIGF1R,
IGF1R, and nuclear AKT expression was lost in multivariate analysis. Exclusion of
clinical variables did not strongly alter these results; all protein markers except PTEN
lost their prognostic value in a multivariate model (Table 6). In addition, patients with
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high pIGF1R expression had significantly poorer DSS outcomes when p was set at 0.1
(HR 0.58, p

= 0.092).
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( < 0.05). Primary
Figure 6. Kaplan-Meier OS curves based on protein marker expression (p
UPS tumor samples (n = 208) were assessed for (A) nuclear AKT, (B) pEGFR, (C) pIGF1R,
and (D) PTEN immunostaining and Kaplan
Kaplan-Meier curves for OS were constructed.
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Figure 7. Kaplan-Meier
Meier DSS curves based on protein marker expression (p < 0.05).
Primary UPS tumor samples (n = 208) were assessed for (A) AXL, (B) pEGFR, (C) pIGF1R,
and (D) PTEN expression and Kaplan
Kaplan-Meier DSS curves were constructed.
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Figure 8. Kaplan-Meier
Meier survival curves based on protein marker immunostaining (p
( <
0.10). Kaplan-Meier
Meier OS curves for (A) AXL and (B) IGF1R expression and (C) Kaplan-Meier
DSS curve for cyclin D1 immunostaining.
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Chapter 4
Dual PI3K/mTOR inhibition has strong antitumorigenic effects in UPS cell lines
and results in IGF1R activation.

As UPS is an uncommon malignancy, cell strains/lines are rare and, therefore, it is
difficult to conduct preclinical investigations of novel therapies. Our laboratory has
established several UPS cell strains and cell lines from patient tumor samples whose
histologies have been verified by pathologists who are experts in the STS Field (Table
1). These bioresources are karyotypically complex and can grow in adherent cultures
over several passages; furthermore, the migration and invasion abilities of these cells
can be assessed in vitro (Figure 9). In addition, some of these cell strains/lines are
tumorigenic in mice and can be utilized to model UPS tumorigenesis and evaluate
therapeutic efficacy in vivo (Figures 9 and 12).
The PI3K/mTOR signaling pathway is active in UPS cell lines and cell strains
After determining that PI3K/mTOR signaling is active in UPS patient tumor samples,
we wished to assess the status of this pathway in UPS cell strains/lines. Currently,
there is no known originating cell or tissue type for UPS; therefore, human
mesenchymal stem cells (hMSCs) were used as a normal control as previous studies
have found molecular similarities between hMSC and UPS cells (33-35). Western blot
analysis determined that PI3K/mTOR signaling is active in a panel of RA-UPS and
sporadic UPS cells as evidenced by high levels of pAKT, pS6K, and p4EBP1 compared
to the hMSC control (Figure 10).
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Figure 9.. UPS cell lines can be used for preclinical investigations. Representative images
of UPS-186 and RIS-819.1
819.1 in adherent culture (magnification: 100x) and after assessment for
migration and invasion in modified Boyden chamber assays (magnification: 200x).
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Figure
igure 10. PI3K/mTOR signaling is active in UPS cell lines and cell strains. Whole cell
lysates obtained from a panel of RA
RA-UPS
UPS and sporadic UPS cell strains and cell lines were
subjected to western blot analysis for total and activated (phosphorylated) AKT,
AKT S6K, and
4EPB1. hMSC served as the normal control.
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A dual PI3K/mTOR inhibitor, PI-103, can block cell proliferation, migration, and invasion
in the RA-UPS cell line RIS-819.1
In order to determine the extent to which PI3K/mTOR signaling supports UPS
tumorigenesis, we elected to pharmacologically inhibit pathway activity using several
dual PI3K/mTOR inhibitors. We first treated the RA-UPS cell line RIS-819.1 with
increasing micromolar doses of PI-103, a dual PI3K/mTOR inhibitor which inhibits PI3K
and mTOR at varying IC50 values (PI3K p110α IC50: 2 nM, mTOR IC50: 30 nM) (232).
We observed a decrease in PI3K/mTOR signaling in RIS-819.1 cells treated with PI103 (range: 0 – 5 µM) over 4 hours (Figure 11A). A reduction in signaling, as measured
by a decrease in pAKT and pS6K, was not achieved until 0.5 µM PI-103 and p4EBP1
attenuation was not noted until 5 µM PI-103. A decrease in cell proliferation with PI-103
treatment was recorded and an EC50 of 0.68 µM was calculated (Figure 11B).
Signaling through the PI3K/mTOR pathway can facilitate cell motility; when
inappropriately activated, these cellular processes can support tumor growth, invasion,
and metastasis (69, 92, 121). Therefore, we assessed the effect of PI-103 on RIS819.1 migration and invasion. Overnight (16 hour) incubation with 0.5 µM of PI-103
resulted in a ~20% decrease in migration and 60% decrease in invasion (Figure 11C).
We assessed the in vivo antitumor efficacy of PI-103 using the RIS-819.1 implant
model (Figure 12). Animals that were treated with 50 mg/kg PI-103 daily had
significantly smaller tumor volumes when compared to the control group (p = 0.045)
(Figure 13A). In addition, a significant reduction in ex vivo tumor weight was observed
in treated animals versus the control (p = 0.031) (Figure 13B).
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Figure 11.

PI-103
103 treatment attenuates PI3K/mTOR signaling, proliferation, and

migration and invasion in vitro
vitro. (A) Immunoblotting of RIS-819.1
819.1 whole cell lysates after PIPI
103 treatment
ment for 4 hours. (B) RIS
RIS-819.1
819.1 cells were treated with increasing concentrations of
PI-103
103 for 96 hours and cell viability was assessed by MTS assay and an EC50 value of 0.68
µM was calculated. Data obtained from duplicate experiments (C) RIS-819.1
819.1 cell migration and
invasion abilities were evaluated after a 16 hour incubation with 0.5 µM PI-103 in modified
Boyden chambers. Data obtained from duplicate experiments. Representative images of the
lower surface of the Boyden chamber is shown at 2
200x magnification. The graphs depict the
mean of duplicate experiments; error bars are the SEM. (* = p < 0.05; ** = p < 0.01; *** = p <
0.001)
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Figure 12. Flow chart describing the general design of in vivo experiments using the
RIS-819.1
819.1 implant mouse model.

Figure 13. Daily

treatment

with

PI-103

reduces tumor volume and weight in vivo. (A) Tumor volume throughout the dosing period
and (B) end-point
point tumor volume for mice harboring RIS
RIS-819.1
819.1 implants and treated with either
vehicle or 50 mg/kg PI-103. Vehicle control: n =7; PI-103: n = 8. (* = p < 0.05; ** = p < 0.01; ***
= p < 0.001)
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XL765, a clinically viable PI3K/mTOR inhibitor, reduces RIS-819.1 tumorigenicity
PI-103 is capable of blocking PI3K/mTOR signaling both in vitro and in vivo;
however, this compound has not moved into clinical trials as it is rapidly metabolized by
mouse models (151). Through a collaborative effort with Sanofi-Aventis, we were
provided with the dual PI3K/mTOR inhibitor XL765 (PI3K p110α IC50: 39 nM, mTOR
IC50: 157 nM) (233). Furthermore, this targeted agent has been evaluated in clinical
trials, both as a single agent and with chemotherapy or targeted therapy, in patients
with with glioma, breast cancer, or other advanced solid tumors (Table 7) (174, 178180, 234). In order to assess the efficacy of XL765 to block PI3K/mTOR signaling and,
thus, PI3K/mTOR-dependent tumorigenesis, we evaluated XL765 treatment in RIS819.1 and an additional cell line, UPS-186, which was generated from a sporadic UPS
(Figure 9). Similar to PI-103, XL765 treatment attenuated signaling through the
PI3K/mTOR pathway in both cell lines after 48 hours of treatment; this signaling
inhibition persisted through 96 hours of treatment (Figure 14A). Both cell lines were
responsive to XL765 treatment, with calculated EC50 values of 1.44 µM (UPS-186) and
1.06 µM (RIS-819.1) (Figure 14B).

Furthermore, XL765 diminished migratory and

invasive capacities of both cell lines after incubation with drug in modified Boyden
chambers (Figure 14C).

56

57

58

Figure 14. XL765 inhibits signaling through the PI3K/mTOR pathway and reduces cell
proliferation in vitro. (A) Levels of activated and total AKT, S6K, and 4EBP1 were detected
via immunoblotting after treatment with micromolar doses of XL765. (B) Cell lines were treated
with escalating doses of XL765. Proliferation was assessed using an MTS assay. (C) UPS-186
and RIS-819.1 cells were incubated in modified Boyden chambers with DMSO or 0.5 µM
XL765 in low-serum (1%FBS in 1x DMEM/F12) conditions for 16 hours. FBS (5%) was used as
a chemoattractant. Representative images of the lower surface of the Boyden chamber is
shown at 20x magnification. The graphs depict the mean of triplicate experiments; error bars
are the SEM. (* = p < 0.05; ** = p < 0.01; *** = p < 0.001)
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We then evaluated XL765 in the RIS-819.1 mouse model of UPS. Animals were
treated twice daily with 30 mg/kg XL765. A 75% reduction in tumor volume was noted
in the XL765-treated arm when compared to the control vehicle group (p < 0.001)
(Figure 15A). Furthermore, average XL765-treated tumor weight was significantly less
than the control (p = 0.025) (Figure 15B).

Treatment with XL765 results in increased IGF1R activation in vitro
Although the PI3K/mTOR pathway was inhibited via XL765, tumor growth was not
abolished in vivo. Therefore, we turned our attention to potential mechanisms of
resistance to PI3K/mTOR blockade. RPPA analysis of a sporadic UPS cell line and
RIS-819.1 revealed that total IGF1R protein levels were elevated following XL765
treatment (Figure 16A), suggesting that upregulation of this receptor could override the
inhibitory effects of a PI3K/mTOR blockade.
Previous studies have indicated that activation of IGF1R and/or the MAPK pathway
could provide a means to evade targeted PI3K/mTOR inhibition (141, 142, 145, 182).
We observed an increase in IGF1R activity, as measured by phosphorylation of the
receptor at Y1135/1136 after 48 and 96 hours of XL765 treatment (Figure 16B). In
addition, we observed an increase in pMEK1/2 with XL765 treatment in UPS-186 at
both 48 and 96 hours; however, we did not observe a similar increase in RIS-819.1 at
96 hours, indicating the potential for cell-line dependent modes of resistance.
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Furthermore, the increase in MEK1/2 phosphorylation did not necessarily correlate with
downstream ERK activation.

Figure 15. Reduction of tumor volume and weight in XL765-treated
treated animals.
animals Twice daily
administration of 30 mg/kg XL765 resulted in significantly decreased (A) in vivo tumor volume
and (B) ex vivo tumor weight when compared to the the control group. Vehicle
ehicle control arm: n =
6 and XL765-treated arm: n = 6. (* = p < 0.05; ** = p < 0.01; *** = p < 0.001)
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Figure 16. Upregulation of IGF1R in response to XL765 treatment. (A) Heat map generated
from RPPA analysis of upstream receptor tyrosine kinases from sporadic UPS cells
cell or RIS819.1 cells treated with XL765 for 48 hours. Displayed values are the linear ratios comparing
protein expression of XL765--treated cells to that of untreated cells. (B) Validation of RPPA data
was performed by western blot analysis for UPS-186 and RIS-819.1 following treated with
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increasing doses of XL765 over 48 or 96 hours. Expression of the indicated proteins was
assessed by immunoblotting.

BGT226 inhibits PI3K/mTOR activity and UPS cell proliferation, migration, and invasion
BGT226 is a commercially available dual PI3K/mTOR inhibitor, which inhibits PI3K
and mTOR activity at a low nanomolar range (175).This drug has been demonstrated
to potently inhibit tumor cell proliferation in multiple cancer models both in vitro and in
vivo, primarily through a G0/G1 arrest (152, 157, 158, 166, 172). In addition, this
compound recently completed a phase I clinical trial in patients with advanced solid
tumors (175); according to clinicaltrials.gov, a phase I/II trial in patients with advanced
solid malignancies, including breast cancer, has also concluded although the results
have yet to be released (Table 7).
BGT226-mediated inhibition of PI3K and mTOR in UPS-186 and RIS-819.1
suppressed phosphorylation of AKT and downstream kinases S6K and 4EBP1 after 2
hours; dephosphorylation was maintained after 96 hours of treatment (Figure 17A).
Substantial antiproliferative effects were detected after 96 hour treatment with low
nanomolar concentrations of BGT226, with calculated EC50 values of 6.81 nM and
4.17 nM for UPS-186 and RIS-819.1, respectively (Figure 17B). Diminished cell
proliferation was linked to both a G1 cell cycle arrest and the induction of apoptosis
(Figure 17C). Interestingly, a greater proportion of apoptotic cells were detected with
increasing concentrations of BGT226 in the RA-UPS cell line RIS-819.1 than in the
sporadic cell line UPS-186.
To examine the effects of BGT226 on UPS cell migration and invasion, UPS-186
and RIS-819.1 were cultured in low-serum (1% FBS in DMEM/F12) to suppress
proliferation and to promote migration towards the chemoattractant (5% FBS in
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DMEM/F12). Cell migration and invasion were reduced in a dose-dependent manner in
both cell lines; however, these processes were not fully inhibited even at the highest
dose of BGT226 evaluated (100 nM) (Figure 17D). Furthermore, although the
concentrations of BGT226 used exceeded EC50 values, an increase in cell death was
not observed during the 16 hour time point (data not shown).
BGT226 reduces in vivo tumorigenecity and results in increased IGF1R activation
Based on the substantial effects of BGT226 treatment seen in vitro, we then
assessed the efficacy of BGT226 treatment in the RIS-819.1 tumor implant mouse
model. After initially treating all arms daily (7 days/week) for 1 week, treatment was
reduced to 5 days/week in the 15 mg/kg BGT226 arm to remedy the observed weight
loss in those animals; treatment continued for an additional 17 days. Oral
administration of BGT226 once daily was sufficient to reduce RIS-819.1 xenograft
volume by 47.4% and 63.6% in the 10 mg/kg and 15 mg/kg arm, respectively, when
compared to the vehicle; in addition, the difference in tumor volumes between the
vehicle and the 15 mg/kg BGT226 group achieved statistical significance (p = 0.05)
(Figure 18A). A trend of decreased tumor weight in the BGT226-treated arms
compared to the control was noted (Figure 18B). Immunohistochemical (IHC) analysis
of downstream effectors of PI3K/mTOR signaling revealed that pAKT, pS6K, and
p4EBP1 were downregulated in the treatment xenografts compared to the vehicle
control, indicating that target inhibition was achieved; however, no differences in Ki67
or CC3 immunostaining was noted (Figure 18C). Interestingly, we detected increased
levels of pIGF1R in BGT226-treated xenografts via both IHC analysis and
immunoblotting (Figure 18D). Similar to the observations made following XL765
treatment, the same phenomenon was seen in vitro via western blot analysis of whole
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cell lysates harvested from UPS-186
186 and RIS-819.1
RIS
treated with BGT226 for 2
and

96 hours (Figure 19A).
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Figure 17. Blockade of the PI3K/mTOR pathway by BGT226 inhibits protumorigenic
processes in vitro. (A) Representative western blots of whole cell lysates from a sporadic
UPS cell line (UPS-186) and a RA-UPS cell line (RIS-819.1) after incubation with increasing
doses of BGT226 for 2 (top) and 96 (bottom) hours. (B) Diminished UPS cell proliferation in
response to 96 hours of BGT226 treatment was measured by MTS assay in UPS-186 and RIS819.1 and the individual EC50s were determined. (C) Cell cycle distribution (left) and apoptosis
levels (right) were evaluated in two UPS cell lines by FACS analysis after 48 and 96 hours of
BGT226 treatment, respectively. (D) The effects of BGT226 on UPS-186 and RIS-819.1 cell
migration and invasion were assessed by modified Boyden chamber assays. Representative
images of cells treated with DMSO or 100 nM BGT226 are displayed (total magnification:
200x). The graphs depict the mean of triplicate experiments; error bars are the SEM. (* = p <
0.05; ** = p < 0.01; *** = p < 0.001)
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Figure 18. Daily administration of BGT226 reduces tumor volume and blocks PI3K/mTOR
signaling, while activating IGF1R in vivo. (A) Hairless SCID mice harboring RIS-819.1
RIS
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implants were treated with either vehicle (n=6) or BGT226 (10 mg/kg or 15 mg/kg, n=7 for both
groups) via daily oral gavage; tumor volumes were measured three times per week. The arrow
indicates the change in the treatment schedule for 15 mg/kg BGT226 group (from 7d/wk to
5d/wk). Values displayed are the mean volumes ± SEM. (* = p < 0.05) (B) Tumor weight was
measured ex vivo. (C) Representative photographs (magnification: 200x) of IHC performed on
RIS-819.1 xenografts from vehicle and BGT226-treated animals for markers of proliferation
(Ki67), apoptosis (CC3), and markers of PI3K/mTOR activity (pAKT, pS6RP, and p4EBP1). (D)
Detection of IGF1R activation (pIGF1R) in vehicle and BGT226-treated xenografts via IHC (top,
magnification: 200x) and western blot (bottom).
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Figure 19. IGF1R is activated in response to BGT226-mediated PI3K/mTOR blockade and
is attenuated by AEW541. (A) Detection of phospho- and total IGF1R in UPS cell lines
incubated with BGT226 for 2 and 96 hours. (B) Western blot analysis of UPS-186 and RIS819.1 cells pre-treated with increasing concentrations of AEW541, then stimulated with 20
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ng/mL IGF1. (C) UPS cell proliferation decreased in the presence of AEW541 ± 20 ng/mL
IGF1. (D) Cell cycle analysis and detection of apoptosis indicated an accumulation of cells in
the G1 phase of the cell cycle and an induction of apoptosis after AEW541 treatment. (E)
Incubation with AEW541 for 16 hours reduced UPS cell migration and invasion. Representative
images of cells treated with DMSO, DMSO + 100 ng/mL IGF1, or 5 µM AEW541 + 100 ng/mL
IGF1 are displayed (magnification: 200x). The graphical representations of the data are the
mean of triplicate experiments; error bars are the SEM. (* = p < 0.05; ** = p < 0.01; *** = p <
0.001)
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Chapter 5
Co-targeting PI3K, mTOR, and IGF1R drastically reduces tumorigenicity.

The IGF1R inhibitor AEW541 hinders UPS cell viability, migration, and invasion
Small molecule inhibitors against IGF1R may also target the highly homologous
insulin receptor (IR). Therefore, we selected the small molecule inhibitor AEW541 to
block IGF1R activation following BGT226 treatment as it displays a higher affinity for
IGF1R over IR. (210). We evaluated the ability of AEW541 to block IGF1R activation by
incubating UPS-186 and RIS-819.1 cell lines with increasing micromolar concentrations
of drug, followed by acute exposure to recombinant IGF1. Western blot analysis
demonstrated that AEW541 reduced IGF1R activation at all concentrations tested, with
the highest level of inhibition achieved at concentrations greater than 1 µM (Figure
19B). While AEW541 downregulated pAKT in both cell lines, it did not strongly effect
the activation status of S6K or 4EBP1, suggesting that IGF1R is not solely responsible
for PI3K/mTOR pathway activation in UPS.
IGF1R can regulate cell growth and proliferation through PI3K/mTOR and/or MAPK
pathway activation (191); accordingly, inhibition of the receptor via AEW541 elicited
strong antiproliferative effects in UPS cell lines (EC50 values: UPS-186 = 4.39 µM and
RIS-819.1 = 4.96 µM) resulting from a significant increase in G1 phase and concomitant
decrease in S phase of the cell cycle and the induction of apoptosis in both cell lines
(Figure 19C and D). Similar to BGT226 treatment, more apoptotic cells were detected
in RIS-819.1 when compared to UPS-186.
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Activation of IGF1R has been linked to tumor invasion and metastasis; therefore,
we investigated the effect of IGF1R inhibition via AEW541 on cell migration and
invasion (195). UPS-186 and RIS-819.1 cells were seeded in low-serum conditions in
modified Boyden chambers; recombinant IGF1 was used as an additional
chemoattractant in order to evaluate the efficacy of AEW541 to block both IGF1R
activation and subsequent promotion of cell migration and invasion. The sensitivity of
RIS-819.1 to AEW541 is further reflected by the significant dose-dependent decline in
both migration and invasion with treatment (Figure 19E). In contrast, the only significant
effects observed in UPS-186 were decreases in invasion with AEW541 concentrations
greater than 2.5 µM. Taken together, these results demonstrate that AEW541
successfully attenuates IGF1R activation, even after stimulation with exogenous ligand,
and exerts anti-tumor effects in vitro in both cell lines tested. While RIS-819.1 and
UPS-186 exhibit varying sensitivities to AEW541, our data suggest that AEW541 could
be used to prevent IGF1R activation resulting from treatment with BGT226.
BGT226 and AEW541 co-treatment does not significantly enhance in vitro antitumor
effects
To investigate potential synergistic drug interactions, UPS-186 and RIS-819.1 cells
were treated with fixed concentrations of BGT226 (range: 0-10 nM) and/or AEW541
(range: 0-2.5 µM) for 96 hours and combination index (CI) values were calculated
(Figure 20A). According to the CI values, synergistic interactions occurred in 80% of
drug combinations tested in UPS-186 and 60% of those in RIS-819.1; however, the
corresponding drug effects for the majority of synergistic drug combinations were not
substantial, with less than 50% cell death after treatment with AEW541 and BGT226
concentrations below their EC50 values. In addition, minimal effects on cell cycle
74

distribution and apoptosis levels in UPS-186 and RIS-819.1 were observed after
treatment with synergistic concentrations of AEW541 and BGT226, further confirming
the lack of antiproliferative effects (Figure 20B).
Despite the lack of antiproliferative effects seen in vitro, synergistic drug
combinations were capable of preventing activation the PI3K/mTOR signaling cascade
and IGF1R after IGF1 stimulation more effectively than either drug alone (Figure 20C).
Furthermore, combination treatment did not alter the phosphorylation status of MAPK
pathway components MEK1/2 and ERK, suggesting that this signaling cascade is not
activated as a compensatory response to PI3K/mTOR and IGF1R blockade (Figure
20D).
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Figure 20. BGT226 and AEW541 act synergistically to block PI3K/mTOR signaling and
IGF1R activation in vitro.. (A) Combination index (CI) values (top), calculated using the
CompuSyn software, and drug effect percentages ([1 – relative cell proliferation] x 100%;
bottom) were obtained by triplicate MTS experiments using UPS-186
186 or RIS-819.1.
RIS
(B) Cell
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cycle distribution (left) and percentage of apoptotic cells (right) were measured in UPS-186 and
RIS-819.1 cells after 48 and 96 hours of treatment, respectively. (C) Effects on IGF1R and
effector molecules of PI3K/mTOR signaling were assayed by western blot following cotreatment with AEW541 and BGT226 and subsequent stimulation with recombinant IGF1. (D)
Expression of activated and total MAPK pathway components MEK1/2 and ERK was evaluated
by western blot analysis after incubation with AEW541 and/or BGT226 and subsequent acute
exposure to IGF1. The graphical representations of the data are the mean of triplicate
experiments; error bars are the SEM. (* = p < 0.05; ** = p < 0.01; *** = p < 0.001)
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In vivo tumor growth is strongly inhibited by combination therapy
Given the negative effect on PI3K/mTOR signal transduction from combination
treatment in vitro, we evaluated combined inhibition of PI3K/mTOR and IGF1R in RIS819.1 xenografts. Mice treated daily with single agent BGT226 or AEW541 had
comparable tumor volumes to the vehicle group (Figure 21A). Strikingly, combination
treatment significantly reduced xenograft volumes by nearly 85% compared to tumors
in the vehicle group (p = 0.020) and by 80% compared to either single agent (AEW541:
p = 0.007; BGT226 p = 0.005); a significant decrease in tumor weight between the
combination and either the control or single agent arms was also noted (p = 0.026,
<0.001, and 0.002; combination versus control, BGT226, and AEW541, respectively)
(Figure 21B). Excitingly, one animal in the combination arm had complete regression of
its tumor within the first 2 weeks of treatment. IHC analysis revealed that AEW541 and
BGT226 co-treatment reduced cell proliferation via decreased Ki67 staining when
compared to vehicle or single agent therapy, but had little effect on apoptosis as
determined by CC3 staining (Figure 21C). PI3K/mTOR signaling was more strongly
inhibited by the combination treatment, as evidenced by downregulation of pAKT,
pS6RP, and p4EBP1; furthermore, AEW541 prevented BGT226-associated IGF1R
activation in the combination arm.
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Figure 21. Combination therapy drastically reduces tumor volume in vivo.
vivo (A) Tumor
volumes of RIS-819.1
819.1 xenografts treated with vehicle ((n=7),
=7), BGT226 (10 mg/kg, n=7), AEW541
(40 mg/kg, n=6),
=6), and combination ((n=6)
=6) are presented as mean volumes ± SEMs. (B) Ex vivo
tumor weight was recorded upon termination of the experiment. (C) Control and inhibitorinhibitor
treated xenografts were subjected to IHC analysis for protein marke
markers
rs of cell proliferation
(Ki67), apoptotic cell death (CC3), and indicators of target inhibition (pAKT, pS6RP, p4EBP1,
and pIGF1R). Representative images are shown (magnification: 200x).
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Chapter 6
Diminished UPS cell migration and invasion after combination therapy is linked
to p27 localization.

Combination of BGT226 and AEW541 has synergistic effects on in vitro cell migration
and invasion
Combination treatment did not significantly alter cell proliferation; however, the
substantial antitumor effects of co-targeting PI3K, mTOR, and IGF1R in vivo suggested
that combination treatment may affect other protumorigenic processes such as cell
migration and invasion. The addition of IGF1 as a chemoattractant enhanced the
migratory and invasive capacities of both UPS-186 and RIS-819.1 in modified Boyden
chambers (Figure 22A). AEW541 treatment alone decreased migration and invasion by
nearly 20% in both cell lines tested. Surprisingly, BGT226-treated cells were able to
migrate and invade at levels similar to or exceeding the control, suggesting that IGF1R
activation may override the inhibitory effects of BGT226. In UPS-186, co-treatment with
AEW541 and BGT226 reduced cell migration and invasion by approximately 50% and
75%, respectively, compared to the DMSO + IGF1 controls. Similarly, we observed a
significant decrease in both migration and invasion (approximately 60% and 80%,
compared to the respective controls) in combination-treated RIS-819.1. Trypan blue
exclusion determined that the concentrations of AEW541 and BGT226 used in
combination did not induce cell death (data not shown).
Negative effects on migration and invasion by combination treatment are linked to p27
nuclear localization and increased RhoA activity
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Nuclear p27Kip1 (p27) is a key regulator of the G1/S transition in the cell cycle;
however, p27 can also localize to the cytoplasm, where it can promote cell motility
through its interaction with and inhibition of the small GTPase RhoA (124). Aberrant
PI3K/mTOR signaling can facilitate the cytoplasmic sequestration of p27 through AKTmediated phosphorylation at T157 and T198, which blocks p27 nuclear import (116118). We performed a nuclear and cytoplasmic fractionation after single agent and
combination treatment in RIS-819.1 cells, followed by western blot analysis to
determine the effects of combination treatment on the subcellular localization of p27.
We observed equal distribution of p27 in the cytoplasm and the nucleus in DMSOtreated cells (Figure 22B). BGT226 decreased cytoplasmic p27, while nuclear levels
were not altered; AEW541 did not significantly affect cytoplasmic or nuclear p27 when
compared to the control cells. Interestingly, combination of AEW541 and BGT226
effectively reduced cytoplasmic p27 levels, while simultaneously increasing nuclear
levels. To determine the potential downstream effect on RhoA, we employed a
colorimetric assay to evaluate RhoA activity in RIS-819.1 cells treated with BGT226
and AEW541 alone and in combination. Cells cultured in low-serum conditions
exhibited low endogenous RhoA activity, which increased after stimulation with FBS
with or without IGF1 (Figure 22C). Combination treatment resulted in a significant 1.5
fold increase in RhoA activity, while either single agent had no significant effect. These
data suggest that PI3K/mTOR signaling contributes to UPS cell migration and invasion
through the promotion of p27 cytoplasmic localization; co-targeting of PI3K, mTOR, and
IGF1R can reduce cytoplasmic p27 while simultaneously increasing nuclear levels.
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Figure 22. Reduction of migration and invasion after co-treatment is associated with
localization of p27 to the nucleus and increased RhoA activity. (A) Combination of
AEW541 and BGT226 reduced UPS cell migration and invasion as evaluated by modified
Boyden chamber assays. (B) p27 localization was determined by nuclear and cytoplasmic
fractionation of cell lysates, followed by immunoblot analysis and calculation of relative protein
levels by densitometry. Fraction purity was assessed by α-tubulin (cytoplasmic) and lamin A/C
(nuclear). (C) The effect of combination treatment on RhoA activity was assayed. Relative
RhoA activity is displayed. (* = p < 0.05; ** = p < 0.01; *** = p < 0.001)
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Chapter 7
Discussion, Conclusions, and Future Directions

UPS is an aggressive subtype of STS devoid of any specificcharacteristics
indicative of the tissue of origin nor any known specific recurring genetic aberrations.
The standard of care is surgical excision with negative margins; for unresectable or
metastatic disease, neoadjuvant systemic chemotherapy or radiation therapy may be
considered. However, UPSs are generally chemoresistant; furthermore, clinical trials
evaluating kinase-targeted therapies which are sometimes moderately effective in other
STS subtypes have reported minimal responses in UPS patients. The aggressiveness
of the disease and the poor response to available therapies is reflected in the five-year
survival rate of only 65-70%. Therefore, novel molecular targets must be identified and
evaluated in order to offer more effacacious therapies and improve UPS patient
outcome.
Previous studies have revealed that active PI3K/mTOR signaling molecules are
negative molecular prognosticators of STS patient OS and DSS (130-132). Moreover,
our laboratory demonstrated that specifically 20% of UPS patients evaluated in a TMAbased study had high levels of pAKT immunostaining, which was indicative of poor
DSS (135). These data indicate that active PI3K/mTOR signaling may contribute to
UPS tumorigenesis and disease progression in a subset of patients and that this cohort
may benefit from targeted therapy against this pathway. Here, we expand upon these
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findings and show that the PI3K/mTOR pathway is indeed active in UPS patient
samples derived from both sporadic and RA tumors by correlating the expression of
several proteins downstream of PI3K and mTOR along with upstream activating RTKs.
Furthermore, we demonstrate that UPS cell strains and cell lines developed in our
laboratory harbor active PI3K/mTOR signaling, allowing us to more fully interrogate this
pathway in preclinical models in vitro and in vivo.
Dysregulation of the PI3K/mTOR pathway has been reported as a driver of
tumorigenesis in several tumor types, including subtypes of STS. Aberrant activation of
the pathway can occur through multiple mechanisms: (1) mutations within the PI3K
isoforms, (2) loss of the tumor suppressor PTEN, and/or (3) the upregulation and/or
abnormal activation of upstream RTKs (61). We are currently sequencing PIK3CA, the
gene encoding catalytic PI3K subunit p110α, to discern whether any activating
mutations are present in UPS tumor samples and cell strains/cell lines; however,
previous studies indicate that PIK3CA mutations are rare in UPS and are most likely
not at the root of pathway activation (235).
PTEN loss may be responsible for unchecked PI3K/mTOR activity, as chromosome
10q is frequently lost in pleomorphic sarcomas (namely, UPS and LMS) and
corresponds to decreased PTEN expression levels (37, 38); in contrast, our data
suggests that PTEN loss is an unlikely driver of UPS sarcomagenesis, as the majority
of patient tumor samples (96%) exhibited PTEN immunostaining. However, a previous
study identified several discrepancies between PTEN IHC and array comparative
genomic hybridization results, suggesting a potential bias in IHC (236). Interrogation of
an expanded cohort of UPS patient tumor samples at the genomic and transcriptomic
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levels could provide a clearer assessment of the PTEN status in these tumors and
better articulate the role of PTEN in UPS tumorigenesis.
The upregulation and/or constitutive activation of RTKs are known drivers of
oncogenesis in multiple subtypes of STS (235, 237-239). To date, no mutations in
candidate RTKs have been detected in UPS patient samples or cell strains/cell lines
(240). Data from Specific Aim 1 demonstrates that there is differential expression of
several RTKs: AXL, EGFR, MET, and IGF1R in tumors from our UPS patient cohort.
Not only do these receptors represent potential activators of PI3K/mTOR signaling and
other protumorigenic pathways (i.e. MAPK), but they could be exploited as molecular
prognosticators of patient survival, predictive biomarkers for therapy response, and
targets for antitumor therapy. However, the contributions of these RTKs in UPS
tumorigenesis are not yet fully understood and should be the topic of future
investigations.
While defining the specific mechanism of PI3K/mTOR activation was out of the
scope of this dissertation, we identified that this pathway is indeed upregulated in UPS
patient-derived tumor samples, cell strains, and cell lines and therefore is an attractive
candidate for anti-UPS targeted therapy. In order to assess the contributions of this
pathway to UPS tumorigenesis, we used three different small molecule inhibitors
against PI3K and mTOR signaling both in vitro and in vivo.
PI-103 and XL765 attenuated PI3K/mTOR signaling and reduced in vitro cell
proliferation, migration, and invasion at micromolar concentrations within the range of
EC50s calculated for other human tumor cell lines (151, 159, 170, 232, 241). In
contrast, low nanomolar concentrations of BGT226 were sufficient to completely
abrogate pathway activation, cause potent antiproliferative effects, and effectively block
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cell migration and invasion, similar to the results obtained in other tumor types (152,
157, 158, 166, 172, 242). Administration of these dual PI3K/mTOR inhibitors as single
agents in a UPS mouse model was sufficient to reduce, but not eliminate, in vivo
tumorigenicity as well as block the activation of PI3K and mTOR effectors. In addition,
cell proliferation and death (as measured by Ki67 and CC3 immunostaining,
respectively) were virtually unaltered in xenografts following BGT226 treatment. The
continued growth, albeit delayed, of UPS xenografts treated with any of these
PI3K/mTOR inhibitors combined with the lack of antiproliferative effects following
BGT226 treatment suggested that compensatory signaling pathways were activated in
response to treatment and were able to promote tumor progression.
Similar to previous studies, we found that dual PI3K/mTOR inhibitors prevented the
compensatory activation of AKT following treatment with rapalogues or other mTOR
kinase inhibitors observed in previous studies (140, 143, 148, 149). However, other
mechanisms of resistance have been reported. The PI3K/mTOR pathway and the
MAPK pathway negatively regulate one another; the blockade of one pathway releases
the inhibitory hold on the other and, in essence, promotes the activation of that
pathway. Several studies have demonstrated increased MAPK activity in tumor cells
treated with anti-PI3K/mTOR therapy; co-inhibition of these pathways is currently being
evaluated in preclinical studies and clinical trials (141, 169, 182, 231, 243, 244). In our
study, we noted an increase in MEK1/2 phosphorylation in UPS cells treated with
increasing concentrations of XL765 without any effect on the activation of the
downstream effector kinase ERK; in addition, no such compensation was detected in
UPS cells after incubation with BGT226. These data indicate that the MAPK pathway is
most likely not involved in acquired resistance to BGT226 treatment and therefore co88

targeting this pathway would have minimal effects on tumorigenesis. Immunoblot
analysis revealed that IGF1R is activated in response to PI3K/mTOR inhibition
following XL765 or BGT226 treatment; furthermore, immunostaining for pIGF1R in
BGT226-treated xenografts detected increased activation of the receptor when
compared to the control.
Previous studies have reported that IGF1R expression and activation increases in
response to targeted inhibition of PI3K/mTOR signaling components. AKT negatively
regulates the FOXO family of transcription factors through phosphorylation-mediated
nuclear import prevention. Anti-AKT therapy in a panel of human cancer cell lines
representing multiple tumor types increased the expression of several RTKs, including
IGF1R, which was dependent on FOXO transcriptional activity; furthermore, the
activation status of these RTKs was elevated relative to the untreated control (142). We
did not assess the status of FOXO-dependent IGF1R transcription in this study;
however, we did note a slight increase in the protein levels of total IGF1R after longterm (96 hour) BGT226 treatment. As increased pIGF1R was detected after 2 hours of
BGT226 treatment, it is likely that activation in response to PI3K/mTOR inhibition
occurs independently of IGF1R protein expression, although increased protein levels
may enhance activation status. Additional studies into the mechanism of IGF1R
upregulation following PI3K/mTOR inhibition are warranted.
Our data, along with other preclinical and clinical studies, support the co-targeting of
PI3K/mTOR pathway components along with IGF1R to enhance the antitumorigenic
effects of either single agent. Treatment of acute myeloid leukemia cells with the
rapalogue RAD001 resulted in compensatory activation of AKT; co-treatment of these
cells with RA001 and an anti-IGF1R mAb prevented the increase in pAKT expression
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(148). Inhibition of PI3K/mTOR catalytic activity in matrix-attached ovarian cancer cell
lines using the small molecule inhibitor BEZ235 resulted in increased IGF1R
expression and activation; subsequent knockdown of IGF1R restored sensitivity to the
drug (145). Similarly, synergistic interactions between a small molecule inhibitor against
PI3K and an anti-IGF1R mAb attenuating IGF1-stimulated growth in a hematopoietic
cell line model (217). In addition, several clinical trials have evaluated the combination
of IGF1R inhibition with targeted therapy against mTOR in patients with advanced solid
tumors to varying degrees of anticancer efficacy (223, 225).
Calculated CI values denoted strong synergistic drug interactions between BGT226
and AEW541. Incubation with these synergistic concentrations did not substantially
improve the overall drug efficacy despite the strong suppression of PI3K/mTOR
pathway activation. This is consistent with other studies demonstrating that
PI3K/mTOR inhibitors generally result in a G0/G1 arrest, as this pathway regulates cell
proliferation by the regulation of G1 cyclins and CDKis at the transcript and protein
levels (245, 246); however, cytotoxic effects have been reported and are usually
dependent on drug concentration (152, 157, 158, 166, 168, 170, 247). Similarly, the
effects of targeted inhibition of IGF1R using AEW541 are generally cytostatic and
results in a G1 cell cycle arrest; apoptosis following AEW541 treatment has been
reported, but is highly dependent on cell sensitivity, drug concentration, and incubation
time (212, 248-251). Likewise, in our study, the reduction in cell viability observed with
single agent BGT226 or AEW541 is largely attributed to a G1 cell cycle arrest and to a
lesser extent an induction of apoptosis, albeit with higher doses of drug. While antiIGF1R therapy can potentiate the cytotoxic effects of systemic chemotherapy (219,
252), combination treatment using small molecule inhibitors against IGF1R and
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PI3K/mTOR did not substantially increase the induction of apoptosis; rather, it merely
enhanced the G1 cell cycle arrest in both cell lines evaluated.
A previous study showed that pharmacologic blockade of PI3K and mTOR catalytic
activity did not strongly affect metastatic breast cancer cell proliferation; however, the
migratory and invasive capacities of these cells were significantly impaired as a result
of decreased levels of cytoplasmic p27 (121). Similarly, UPS cell migration and
invasion was strongly downregulated by targeted inhibition of PI3K, mTOR, and IGF1R,
despite minimal effects on cell proliferation, cell cycle progression, and apoptosis.
Furthermore, co-treatment resulted in a significant decrease of cytoplasmic p27 while
concomitantly increasing nuclear levels of the protein; these alterations in p27
localization corresponded to an increase of RhoA activity. In addition, the increased
levels of nuclear p27 could result in a G1 cell cycle arrest and thus reduce UPS cell
proliferation. Interestingly, the levels of cytoplasmic p27 decreased dramatically with
single agent BGT226 treatment without affecting cell motility, though this could be
attributed to the lack of IGF1 stimulation prior to fractionation. Our data shows that
IGF1 stimulation renders UPS cells insensitive to the negative effects of BGT226 on
migration and invasion. It is possible that IGF1-mediated IGF1R stimulation increases
cytoplasmic p27 to a level that cannot be affected by BGT226 treatment.
While the cytoplasmic localization of p27 and corresponding inhibition of RhoA
activity surely contribute to UPS cell motility, it is evident that additional mechanisms of
cell migration and invasion are involved. Both mTORC1 and mTORC2 have been
shown to facilitate IGF1-stimulated cell migration (253). Furthermore, mTORC2 has
been demonstrated to regulate actin cytoskeleton reorganization and cell migration
through Rho family GTPase activity (254, 255). Activation of Rac1 in response to PI3K
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activity requires the Rac GEF PIP3-dependent Rac exchanger 1 (P-REX1) and is
essential for lamellopodia formation in response to growth factor stimulation (256). A
previous study reported that P-REX1 can be activated by IGF1 and enhances the
IGF1-mediated phosphorylation of AKT through direct interaction; furthermore, P-REX1
can also interact with mTORC2 to promote Rac1 activation (92, 257). In addition,
constitutively active AKT can enhance Rac1 activation and vice versa, indicating the
potential for a positive feedback loop during PI3K-mediated cell migration (258). Our
data demonstrate that phosphorylation of AKT at S473 is abrogated by co-treatment,
indicating that mTORC2 function is compromised. Co-treatment with AEW541 and
BGT226 inhibit IGF1R and mTORC2, which could suppress Rac1 activity through the
elimination of the P-REX1/mTORC2 interaction and thus reduce cell migration.
Investigations regarding the pro-migratory activity of mTORC2 and its effect on Rac1
activation following co-treatment with BGT226 and AEW541 should be conducted to
better articulate its role in UPS cell migration and invasion.
In addition, IGF1R activation and resulting downstream PI3K/mTOR signaling
regulates several matrix metalloproteinases (MMPs) which degrade both extracellular
matrix and non-matrix substrates in order to facilitate cell migration and invasion (259263). In addition, MMPs can increase IGF1 bioavailability through the degradation of
insulin-like growth factor binding proteins and thus enhance IGF1R activation and
promote cell survival and growth during the invasion process (264-266). The coinhibition of IGF1R and PI3K/mTOR could substantially reduce MMP production and
explain the profound decrease in UPS cell invasion observed in vitro. Future studies
should evaluate the levels of MMP production and secretion following combined
inhibition of IGF1R, PI3K, and mTOR.
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Although in vitro cell viability was not greatly affected by BGT226 and AEW541 at
synergistic concentrations, the “vertical blockade” – that is, targeting multiple
components within the same pathway – has proven effective in mouse models of other
cancers targeting PI3K/mTOR signaling (167, 267-269). Indeed, we found that
combination therapy administered to a mouse model of UPS resulted in drastically
decreased tumor volume and weight when compared to the control which could
attributed in part to a reduction in cell proliferation as well as improved target inhibition.
However, we did not observe complete reduction in tumor cell proliferation, nor any
difference in apoptotic cell death that could account for the significant difference in
tumor volume and weight between the combination-treated and the control arms. Given
the importance of PI3K/mTOR signaling and IGF1R activity for invasive tumor growth
and angiogenesis (62, 160, 212, 270-275), co-targeting of PI3K, mTOR, and IGF1R
would have a substantial negative effect on these tumorigenic processes, thus limiting
the supply of nutrients and oxygen to tumor cells and preventing primary tumor
expansion and metastatic spread, while possibly promoting cell death in an apoptosisindependent manner.
Excitingly, one tumor completely regressed within two weeks of treatment onset,
suggesting that combination therapy may be highly effective in UPS, resulting in
disease-stabilization or instances of tumor regression. However, an increase in tumor
growth, though slight, was noted in the remaining animals receiving combination
treatment, suggesting that long term treatment may reveal other potential mechanisms
of adaptive resistance (i.e. activation of the MAPK pathway or an oncogenic RTK)
which could be incorporated into combination therapy. Future studies should focus on
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the effect of in vivo combination therapy on long-term survival while exploring the
possibility for compensatory activation of other protumorigenic molecules or pathways.
Numerous preclinical studies have supported developing anti-IGF1R targeted
therapies for the treatment of different human malignancies (193-195, 202, 205, 208,
212). Phase I and II clinical trials evaluating mAbs against IGF1R for the treatment of
advanced solid tumors of various histologies demonstrated anticancer activity in some
patients (209, 224, 276-280); however, the majority of advanced phase clinical trials
evaluating IGF1R as a therapeutic target have been discontinued due to a lack of
efficacy in the majority of patients (213-216). Targeting IGF1R with mAbs increases
receptor internalization, while IR expression increases in response to anti-IGF1R
therapy (213). In addition, targeted inhibition of IGF1R has been linked to dysregulated
endocrine signaling, which promotes growth hormone production and the subsequent
increase in IGF1 and insulin production (213). The resulting increase in IR activation
could attenuate the antitumor response to IGF1R inhibition or even promote disease
progression in the presence of treatment (191, 208).
Despite the disappointing reports from Phase II and III clinical trials, evidence
demonstrating anti-IGF1R efficacy in some patients raises the possibility that a subset
of patients could benefit from this type of therapy and highlights the need for predictive
biomarkers to identify these populations. We found that pIGF1R expression correlated
to poorer OS and DSS in our cohort of sporadic and RA-UPS patients. In addition, total
and activated IGF1R were more highly expressed in RA-UPS patient tumors samples
compared to the majority of sporadic UPS samples. However, a small subset (25-30%)
of sporadic UPS tumor samples expressed high levels of IGF1R and pIGF1R. RA-UPS
are generally more aggressive than sporadic UPS, as illustrated by the dramatically
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shortened DSS times and higher propensity for recurrent disease in RA-UPS patients
(60); however, no known molecular alterations have yet been identified as unique
markers of disease setting. While no protein markers in our panel could differentiate
between disease settings with complete specificity, pIGF1R may indicate overall
disease aggressiveness, as it was expressed predominantly in RA-UPS and in a
subset of sporadic UPS. Further studies should include samples representative of
recurrent and metastatic disease when examining the utility of pIGF1R as a biomarker
for disease stage, patient response to therapy, and DSS times.
These data are further supported by our in vitro results. pIGF1R expression is
elevated in response to PI3K/mTOR inhibition both in vitro and in vivo and combined
inhibition of all three molecules using BGT226 and AEW541 is synergistic.
Interestingly, the RA-UPS-derived cell line RIS-819.1 was more sensitive to targeted
inhibition of PI3K, mTOR, and IGF1R than the sporadic UPS cell line UPS-186 as
evidenced by increased apoptosis with single agent or combination treatment and an
enhanced G1 cell cycle arrest following co-treatment. However, UPS-186 still exhibited
compensatory IGF1R activation in response to PI3K/mTOR signaling blockade and
was sensitive to combined inhibition with BGT226 and AEW541. Together, these
observations and data indicate that activated IGF1R may not necessarily differentiate
between disease settings, but rather could be utilized as a marker of tumor aggression,
a predictor of patient response to therapy, and/or a molecular prognosticator of
survival.
Conclusions and future directions
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UPS is a devastating malignancy for which there are limited therapeutic options for
patients and no known biomarkers to predict patient response to therapy. In this study,
we demonstrate that targeted PI3K, mTOR, and IGF1R in tandem exerts strong
synergistic antitumor effects in vivo and downregulates UPS cell migration and invasion
in part through the cytoplasmic sequestration of p27. Our data support co-targeting this
pathway in a vertical blockade as a novel therapeutic avenue for these patients. In
addition, we propose that IGF1R is a molecular prognosticator for patient outcome and
may be useful in the identification of extremely aggressive subtypes of RA and sporadic
UPS. Future investigations are necessary to understand the complete mechanism by
which IGF1R and PI3K/mTOR signaling regulate UPS cell migration and invasion in
addition to modulation of p27 subcellular localization. Additionally, the interrogation of
IGF1R and components of the PI3K/mTOR pathway could further validate the utility of
these molecules as predictive biomarkers for UPS patient response to therapy; in
addition, studies examining the effects of combined inhibition of PI3K, mTOR, and
IGF1R on long-term survival could provide additional support the evaluation of this
combination cohorts of UPS patients.
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Chapter 8
Appendices

Appendix 1
The manuscript described below has been submitted for publication and involves the
data discussed in Specific Aim 2 and Specific Aim 3 from this dissertation.

May CD, Bolshakov S, Landers SM, Ingram DR, Ma XY, Kivlin CM, Kalam AA, Lazar
AJ, and Torres KE. Co-targeting PI3K, mTOR, and IGF1R with small molecule
inhibitors for the treatment of undifferentiated pleomorphic sarcoma. Submitted for
publication.
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Appendix 2
The manuscript described below has been submitted for publication and involves the
data discussed in Specific Aim 1 from this dissertation. Data from this Aim were
previously presented at the 68th Society for Surgical Oncology Annual Cancer
Symposium, March 2015, Houston, Texas.

Roland CL, Dineen SP, Watson KL, Al Sannaa GA, Feig R, May CD, Ingram DR, Wang
WL, Lazar AJ, Ravi V, Hunt KK, Cormier JN, Feig BW, and Torres KE. Variations in
Protein Expression are Associated with Survival Outcomes in Patients with
Undifferentiated Pleomorphic Sarcomas. Submitted for the 68th Society of Surgical
Oncology Annual Cancer Symposium, March 25-28, 2015, Houston, Texas.
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Appendix 3
The manuscript described below has been submitted for publication and contains data
from a side project investigating the receptor tyrosine kinase AXL for its role in
liposarcomagenesis.

May CD, Garnett J, Ma XY, Ingram DR, Al-Sannaa GA, Demicco EG, Han L, Zhang Y,
Kivlin CM, Bolshakov S, Landers SM, Kalam AA, Wang WL, Lazar AJ, Pollock RE, Lev
D, and Torres KE. Role of AXL as a potential therapeutic target for pleomorphic and
dedifferentiated liposarcomas. Submitted for publication.
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